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General introduction and outline of the thesis 

General introduction and outline of the thesis 
Background 
Approximately 45% of the tumors of the stomach initially respond to chemotherapy, 
whereas 55% of the tumors are primarily resistant. Of the responding tumors the 
majority acquires secondary resistance. The mechanism of the resistance is 
basically unknown.lt is likely that a wide variety of drug resistance mechanisms 
are operational. 
Both primary and secondary resistance could be related to isoenzymes of the 
glutathione S-transferases (GSTs), a family of enzymes involved in cellular 
detoxification of xenobiotics. Increasing evidence suggests that malignant cells 
may be capable of using these enzymes for protection against antineoplastic 
agents. Moreover, several other mechanisms have been described that mediate 
resistance, such as proteins that afford increased rates of drug efflux fromthe cell, 
e.g. P-glycoprotein (Pgp) and multidrug resistance associated protein (MRP). 
Most anticancer drugs show greater toxicity for rapidly proliferating cells, which 
suggests an explanation forthe greater responsiveness of rapidly growing tumors 
to chemotherapy (and allows partly understanding of the problem of resistance). 
In gastric cancer there are no data about cell proliferation in relation to drug 
sensitivity. 
Given the combined expertise of the departments of Gastroenterology and 
Medical Oncology, we selected to study the significance of GSTs and cell 
proliferation, with respect to their role in chemotherapy resistance of stomach 
cancer. 
Outline of the study 
In Chapter 2 a detailed review of the literature about chemotherapy in gastric 
cancer is presented. Subsequently a short overview on the role of GSTs in human 
cancer is given in Chapter 3. In Chapter 4 the significance of cell proliferation 
measurement in gastric cancer is discussed. 
Chapter 5 describes our studies on the immunohistochemical expression of GST 
class Alpha and Pi in normal and malignant gastric tissue. In Chapter 6 our data 
on expression of GSTs in gastric carcinoma and adjacent normal gastric tissue 
obtained by biochemical and immunohistochemical methods are compared. 
In Chapter 7 the relationship between GST expression and survival was studied 
in49patients with primary gastriccarcinoma.Chapter8 describes the measurement 
of cell proliferation in normal and malignant gastric tissue. Acomparison between 
two different methods to examine cell proliferation is made. In chapter 9 results 
from a study about the role of GSTs, Pgp, MRP and cell proliferation as 
parameters for respons to chemotherapy in gastric cancer are presented. 
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Chemotherapy of gastric cancer 
Summary 
Patients with gastric adenocarcinomas have a poor prognosis. Because curative 
surgery is often impossible (metastatic disease) or extremely difficult (locally 
advanced tumors), and the majority of patients undergoing curative resection 
relapse, chemotherapy has been actively studied in gastric cancer. Many drugs 
have shown activity; however, single-agent chemotherapy failed to demonstrate 
increased survival benefit. Several combination regimens have been developed 
with high activity in locally advanced and metastatic disease. Among them are 5-
fluorouracil plus high dose methotrexate plus doxorubicin (FAMTX), etoposide 
plus doxorubicin plus cisplatin (EAP), etoposide plus leucovorin plus 5-f luorouracil 
(ELF), and epirubicin plus cisplatin plus 5-fluorouracil (ECF). Although the 
response rates of these schedules are encouraging, the toxicity is considerable. 
Randomized trials comparing chemotherapy with best supportive care showed 
an increase in overall survival and in quality-of-life. 
Up to now adjuvant chemotherapy in curatively resected gastric cancer patients 
has failed to improve survival as compared with surgical controls. Phase II trials 
with preoperative chemotherapy have shown very promising results, but results 
of randomized trials should be awaited to judge the real value of this approach. 
At this moment it cannot yet be estimated whether preoperative chemotherapy 
does positively influence the resection rate and survival of patients with clinically 
resectable tumors. 
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Introduction 
Because surgery is the only treatment modality with curative intention, there is no 
doubt that surgery is the treatment of choice in localized gastric carcinoma. 
However, at diagnosis, 75% of all patients have disseminated disease1. Even 
among the subgroup of patients who are able to undergo potentially curative 
resection, relapse is common. Since 5-year survival ranges only from 10 to 15% 
of all patients with newly diagnosed disease, the use of chemotherapy in patients 
with gastric cancer has been a subject of great interest. 
Until recently gastric cancerhas been regarded as a tumorin which chemotherapy 
is only marginally active. However, recent advances have shown encouraging 
results2 3. This article reviews the most important results of phase ll-lll trials on 
chemotherapy of gastric cancer and of clinical trials on adjuvant and neoadjuvant 
chemotherapy published in the English literature from 1967 to April 1995, 
including those published in the English language in Japanese journals. The 
reports were obtained from a MEDLINE data base search and from cross-
reference from other published journals. 
Single-agent chemotherapy 
Over the last decade, much effort has been put into identification of active single 
agents in gastric cancer. Table 1 lists a number of agents and their observed 
response rates in gastric cancer. Direct comparisons of these responses are 
difficult because of different patient selection factors. Furthermore, evaluating 
chemotherapy in gastric cancer often involve some bias, as in many patients no 
bidimensially measurable disease parameters are available. 
At present, 5-fluorouracil (5-FU), doxorubicin (orits derivate epirubicin), mitomycin 
С and cisplatin have been identified as exhibiting modest or moderate single-
agent activity in patients with advanced gastric cancer45. Recently activity has 
been described for the new chemotherapeutic agents taxotere6 and irinotecan7. 
5-FU is the most extensively studied drug in this disease. It was, until recently, 
used as an i.v. bolus administration, yielding a response rate of about 20%8 9. 
Because 5-FU is cell cycle specific and has a short plasma half-life, and because 
at any time approximately 3% of tumor cells are cycling, a protracted continuous 
i.v. infusion of this drug has been investigated10. This type of administration was 
piloted in colorectal cancer, yielding a significant improvement of response 
compared with an i.v. bolus schedule11. Although there has been no randomized 
trial in gastric cancer, there has been a small study of protracted infusion of 5-FU, 
demonstrating an interesting high response rate of 31 %12. The adverse effects 
of 5-FU are in general mild. The major side-effects of 5-FU are mucositis, diarrhea, 
myelosuppression and, especially if infusional therapy is given, the hand-foot 
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syndrome 5-FU has been a common element in most combination chemotherapy 
regimens for gastric cancer 
Mitomycin C, an antitumorantibioticthat probably acts as an alkylating agent, also 
hasbeen extensively used mthetreatmentofgastnccancer The overall objective 
response rate for mitomycin С has been approximately 30%13 Its major toxic 
effect is delayed and cumulative myelosuppression 
Doxorubicin, an anthracyclme antibiotic, is a potent drug in gastnccancer, yielding 
a response rate of 17%513 Its most critical toxicity is irreversible myocardial 
damage, after exceeding a dose of 550 mg/m2 Epirubicin, a derivate of 
doxorubicin, thought to be less cardiotoxic, has also been shown to have 
significant activity in gastric cancer (response rate approximately 19%)13 
Cisplatin, a heavy metal compound acting as an alkylating agent, has been 
studied as a single-agent, giving major responses in 19% of patients, including 
those previously treated5 Despite this activity, it has the disadvantages of 
nephrotoxicity, requiring hydration, and marked emesis, which in most of the 
cases can be alleviated by new antiemetic drugs The less nephrotoxic and 
emetogenic analogue of cisplatin, carboplatin, has not been found to be active 
in gastric cancer14 
Taxotere, a representative of the taxoids, is a new importantantitumor compound, 
acting as a mitotic spindle poison and inducing a mitotic block15 A response rate 
of 23% was achieved in a small phase II trial6 Its dose-limiting toxicity is 
myelosuppression Innotecan.atopoisomerase inhibitor, is another new cytotoxic 
agent, also with a moderate activity in gastric cancer7 Its main toxicity is diarrhea 
Both taxotere and innotecan are interesting new anticancer agents, and deserve 
further investigation in combination chemotherapy regimens 
Other chemotherapeutic agents that have been studied in advanced gastric 
cancer with modest or minimal activity are shown in Table 1 Complete responses 
are extraordinary uncommon with single agents, even with those having the 
highest reported activity Responses are generally of brief duration and without 
a significant impact on survival No single-agent treatment in gastric cancer can 
be recommended as a clinical routine at present The role of single-drug clinical 
trials therefore is to identify agents with activity that can subsequently be 
evaluated when incorporated into multidrug regimens 
17 
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Table 1 
Single-Agent chemotherapy in advanced gastric cancer. 
Drug No. 
Antimetabolites 
5-FU (protracted infusion) 
5-FU (bolus) 
Carmofur (oral) 
Hydroxyurea (oral) 
Methotrexate 
Triazinate 
Antibiotics 
Mitomycin-C 
Epirubicin 
Doxorubicin 
Heavy Metals 
Cisplatin 
Carboplatin 
Alkylating Agents 
BCNU 
Chlorambucil 
Methyl-CCNU 
Miscellaneous 
Etoposide 
Bisantrene 
Mitoguazone 
Gemcitabine 
Taxotere 
Irinotecan 
of évaluable 
patients 
13 
392 
31 
31 
28 
26 
211 
80 
141 
139 
41 
33 
18 
37 
25 
26 
31 
41 
26 
60 
Overall response 
rate (%) 
31 
21 
19 
19 
11 
15 
30 
19 
17 
19 
5 
18 
17 
8 
12 
4 
3 
2 
23 
23 
Ref. 
12 
8,9 
5 
5 
41 
41 
4,5,13 
5,13 
5,13 
5 
14 
5 
42 
5 
5 
43 
44 
45,46 
6 
7 
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Combination chemotherapy 
Cytotoxic combinations in gastric cancer have been derived from single agents 
and scheduled to maximize the antitumor effect while minimizing the toxicity. 
Table 2 lists a number of more frequently used combination regimens, their 
observed response rates and median survival time. Until recently, the most 
extensively used combination in gastric cancer was 5-FU, doxorubicin and 
mitomycin С (FAM)16. This schedule resulted in a response rate of approximately 
30% and a median survival time of 5 - 9 months (Table 2). A number of similar 
combinations replacing mitomycin С in the FAM regimen with BCNU (FAB), 
methyl-CCNU (FAMe), or cisplatin (FAP) have been introduced, but without 
improvement of treatment results. The wide scale use of FAM orother combinations 
like FAMe or FAP is a controversial issue, since in randomized studies, they have 
not shown a significant advantage over 5-FU alone1719. 
Klein era/, developed the FAMTX regimen, which includes the administration of 
high doses of methotrexate followed by 5-FU on day 1, and of doxorubicin on day 
15, every 4 weeks. The methotrexate is given 1 h prior to 5-FU to modulate its 
action. They obtained a response rate of 58% in 116 patients, and a median 
survival of 9 months and for responders of 15 months20. Subsequent studies by 
other investigators yielded contradictory results (Table 2). However, in a randomized 
trial conducted by the EORTC, FAMTX induced a significantly higher remission 
rate (41 versus 9%) and a significantly longer median survival time (44 versus 29 
weeks) than FAM21. Furthermore, hematological toxicity was lower in the FAMTX 
regimen. Although in this study the response rate seen with the FAM regimen is 
less than seen in previous studies, these results support the place of FAMTX as 
the best standard therapy for further randomized trials. Further attempts at 
refining the scheduling of FAMTX have been initiated, either with modulation of 
5-FU or alterations in schedule and in substitution of adriamycin by epirubicin. 
5-FU is the most extensively studied single agent in gastric cancer. As in the 
laboratory the efficacy of 5-FU can be enhanced by modulation with leucovorin22, 
Machover ef a/.23 developed a schedule in which 5-FU was combined with high-
dose leucovorin. He obtained a response rate of 48% in 27 patients with gastric 
cancer. Subsequent studies by others yielded contradictory results (Table 2). 
However, recent studies with high-dose 5-FU and high-dose leucovorin are 
promising, and will be tested in a randomized trial in the EORTC. 
In the late 1980s, Preusser et al. developed a cisplatin-containing regimen, 
combining etoposide and adriamycin with cisplatin (EAP)24. The peculiarity of this 
protocol is that it is the only combination regimen in advanced gastric cancer that 
does not utilize 5-FU. They obtained a response rate of 64%, including 2 1 % 
complete responses. The median survival of all patients was 9 months. The 
subsequent experience from different centres confirms the activity of this regimen 
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(Table 2). This regimen, however, did appear to be very toxic. This was confirmed 
in a randomized trial comparing EAP with FAMTX. The trial was stopped early 
because of no apparent difference in response, but a significantly higher toxic 
death rate with EAP25. 
Wilke et al. designed the etoposide/leucovorin/5-FU (ELF) combination26 as a 
default study for patients with cardiac or other medical conditions or of advanced 
age, who were thought not likely to tolerate EAP. This combination achieved a 
response rate of 53%, including 8% complete responses. A median survival time 
of 11 months was observed. Because of the encouraging results and the low 
toxicity profile, the EORTC currently is comparing ELF, 5-FU combined with 
cisplatin and FAMTX in a randomized phase III trial. 
The combination of 5-FU and cisplatin has been evaluated in 6 studies in 261 
patients. Overall response rates of 24 - 45% with median survival times of 4 -11 
months have been reported (Table 2). 
In a study in colorectal cancer patients11,5-FU given as a continuous i.v. infusion 
yielded a higher tumor response (30 versus 7%) with less toxicity than an 
intermittent bolus schedule given daily for 5 days every month. In a small non-
randomized trial in gastric cancer patients, continuous infusion of 5-FU yielded 
a respons rate of 31 %12, whereas 5-FU given as an i.v. bolus was known to give 
a response rate of about 20%89. These results have made it an attractive base 
for new combination chemotherapy regimens in gastric cancer. Two other drugs 
were added to the infusional 5-FU: cisplatin because of its activity in this disease13 
and potential synergy with 5-FU, andtheanthracycline epirubicin. This combination 
has shown high antitumor activity (response rate 36-71%) with moderate 
toxicity2729. Thus, ECF is an effective form of palliative treatment for patients with 
advanced gastric carcinoma. Because of the encouraging results, Findlayefa/. 
are now testing the ECF regimen in a multicentre phase III study with FAMTX, 
using patient survival and quality-of-life as major end points. 
Three studies compared chemotherapy with best supportive care. A study by 
Murad et a/.30 showed a survival benefit for chemotherapy in patients with 
advanced gastric cancer Patients were randomized to a modified version of 
FAMTX or best supportive care. In the middle of the study the randomization was 
interrupted because of strong evidence of benefit in the treatment arm. Further 
patients were accrued to the treatment arm, and by the end of the study 30 
évaluable patients had received chemotherapy and 10 supportive treatment only. 
The median overall survival of the treated group was 10 months and that of the 
control group only 3 months. A phase III study by Pyrhönen et al. comparing 5-
FU, epirubicin and methotrexate (FEMTX) with best supportive care has also 
shown a significant prolongation of progression-free time (p<0.02) as well as 
survival (p<0.007) in the FEMTX group compared with the control group31. In a 
small Swedish pilot study, initial chemotherapy (ELF or leucovorin with 5-FU) was 
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compared with best supportive care32. Overall survival was significantly better in 
the group of patients randomized to chemotherapy (median 10 months) than in 
those allocated to the best supportive care (median 4 months). In the overall 
assessment of quality-of-life, conducted to a structured questionnaire, more 
patientsin the primary chemotherapy group than in the bestsupportive care group 
were improved or continued to have high quality-of-life for at least 4 months 
(p=0.06). 
In conclusion, the newchemotherapeutic developments have led to a step ahead 
in the systemictreatment of gastric cancer. Approximately half of the patients with 
metastasized disease may benef itf rom chemotherapy with the new combinations 
by amelioration of symptoms or prolongation of survival. 
Table 2 
Results of more frequently used combinations for the treatment of advanced gastric 
cancer 
Combination Evaluable Response Median survival Ref. 
Patients rate (%) time (months) 
(range) 
FAM and modifications 
FAP 
FAB 
FAMe 
FMe 
FAMTX and modifications 
E*AP and modifications 
E*LF and modifications 
FEMTXP 
FEMTX 
FLP 
FLEP 
FLE 
HLFP 
FP and modifications 
ECF 
FL and modifications 
941 
232 
303 
141 
224 
637 
509 
222 
41 
32 
100 
318 
37 
40 
261 
235 
101 
29 (12 -65) 
37 (20 -56) 
44 (24 -51) 
25 (15 -47) 
19 (9 -40) 
32 (0 -58) 
48(13 -73) 
32 (15 -53) 
34 (33 -35) 
25 
61 (48 -69) 
41 (15 -67) 
38 
58 
38 (24 -45) 
59 (36 -71) 
20 (0 -48) 
Abbreviations: A = adriamycin, В = BCNU, E = epirubicin, E* = etoposide, 
F = 5-fluorouracil, H = hydroxyurea , L = leucovorin, M = mitomycin-C, 
Me = Methyl-CCNU, MTX = methotrexate, Ρ (or C) = cisplatin, NA = not available 
5 - 9 
4 -12 
6 - 8 
6 -13 
3 - 5 
3 -11 
6 -10 
6 -12 
NA 
8 
9 -14 
8 
NA 
12 
4 -11 
8 - 9 
5 - 6 
16-19.47-67 
54.68-75 
76-80 
48 56 62,68.81,82 
48,56.83-86 
20,21.25,30,87-94 
24,25.67,95-103 
94,97,104-107 
108-110 
111 
112-115 
55 93,115-119 
120 
121 
94 122-126 
27-29,122 
23,127-130 
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Adjuvant chemotherapy 
The roleof adjuvant chemotherapy in gastric cancerhas been extensively studied 
over the last three decades, being the first attempt to improve the prognosis of 
resected gastric cancer patients. The most important studies of adjuvant 
chemotherapy that have used a surgery alone control arm are summarized in 
Table 3 and 4. 
Up to now it could not be shown that adjuvant chemotherapy has a positive impact 
on survival as compared with surgery alone and a recently published meta-
analysis ruled out an only small survival benefit produced by the adjuvant 
treatment programmes used so far33 3". These negative results do not necessarily 
mean that the concept of adjuvant chemotherapy of gastric cancer is not 
working35 38. In the published trials chemotherapy consisted of only marginally 
active schedules and the patient numbers were in most of these trials too small 
to allow an appropriate statistical conclusion. Furthermore, in most trials, a 
homogeneous surgical approach and a surgical and pathological quality control 
was not mandatory. Therefore, well-designed trials with new and active 
chemotherapy regimens as well as precisely defined surgery and surgical quality 
controls are needed. At this moment adjuvant chemotherapy of gastric cancer 
remains an experimental approach and is not indicated outside clinical trials. 
22 
Chemotherapy of gastric cancer 
Table 3 
Results of randomized trials of adjuvant single-agent chemotherapy following 
curative resection for advanced gastric cancer. 
Treatment 
Surgery alone 
Thiotepa 
Surgery alone 
FUDR 
Surgery alone 
Cisplatin ¡.p. 
Surgery alone 
Mitomycin С 
Surgery alone 
Mitomycin С 
Surgery alone 
Mitomycin С 
Surgery alone 
Carbon absorbed 
Mitomycin С i.p. 
Surgery alone 
Ftorafur 
No. of Percent 
patients survival 
randomized after no. 
315 
301 
212 
185 
34 
33 
66 
68 
37 
33 
223 
207 
25 
24 
56 
59 
of years 
19/5 
21/5 
34/3 
32/3 
24/5 
21/5 
26/5 
41/5 
62/5 
21/5 
43.5/5 
52.5/5 
27/3 
69/3 
Stage II: 31/3 
Stagelll: 22/3 
Stage II: 69/3 
Stagelll: 41/3 
Median 
survival 
(months) 
NA 
NA 
NA 
NA 
16 
17 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Stage II: 
Stagelll: 
Stage II: 
Stagelll: 
34 
22 
60 
34 
Ρ 
NS 
NS 
NS 
0.025 
0.001 
NS 
O.005 
NS 
Ref. 
131 
132 
133 
134 
135 
136 
137 
138 
Abbreviations: FUDR = 5-fluorodeoxyuridine, i.p. = intraperitoneal, NA = Not 
Available, NS = not significant 
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Table 4 
Results of randomized trials of adjuvant combination chemotherapy following 
curative resection for advanced gastric cancer. 
Treatment 
Surgery alone 
FMe 
Surgery alone 
FB 
Surgery alone 
C/MTX/FA/CR 
Surgery alone 
F/VCR/MTX/C 
induction + F/M 
F/M 
Surgery alone 
FAM 
Radiotherapy 
Surgery alone 
FMe 
FMe/levamisole 
Surgery alone 
FMe 
Surgery alone 
FMe 
Surgery alone 
FMe 
No. of 
patients 
randomized 
71 
71 
54 
49 
34 
29 
130 
140 
141 
145 
138 
153 
69 
75 
69 
47 
41 
68 
66 
89 
91 
Percent 
survival 
after no. 
of years 
31/5 
44/5 
42/5 
57/5 
10/5 
11/5 
NA 
NA 
NA 
13/5 
9/5 
18/5 
50/5 
50/5 
50/5 
38/4 
55/4 
NA 
NA 
57/2 
57/2 
Median 
survival 
(months) 
33 
not reached 
NA 
not reached 
15 
15 
16 
14 
18 
12 
NA 
NA 
NA 
33 
not reached 
NA 
NA 
33 
37 
Ρ 
0.003 
NS 
NS 
NS 
NS 
NS 
0.03 
NS 
NS 
Ref. 
139 
140 
141 
142 
143 
144 
145 
146 
147 
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Table 4 (continued) 
Treatment 
Surgery alone 
M/F/Cyt + F 
M/Ftorafur/Cyt+ 
Ftorafur 
Surgery alone 
Radiotherapy 
FAM 
Surgery alone 
FA 
Surgery alone 
M/Tegafur/PSK 
Surgery alone 
FAM (1 year) 
Surgery alone 
FAM 
Surgery alone 
F/Vinblastine/C 
Surgery alone 
M 
M/F/Cyt 
Surgery alone 
M/F/Cyt 
No. of 
patients 
randomized 
79 
81 
83 
145 
153 
138 
64 
61 
118 
137 
148 
133 
93 
83 
26 
27 
38 
42 
40 
34 
53 
Percent 
survival 
after no. 
of years 
51/5 
68/5 
63/5 
20/5 
12/5 
19/5 
33/5 
32/5 
46/15 
57/15 
35/5 
46/5 
NA 
NA 
18/5 
16/5 
56/5 
64/5 
67/5 
29/5 
45/5 
Median 
survival 
(months) 
NA 
NA 
NA 
15 
13 
17 
31 
36 
NA 
NA 
NA 
NA 
28 
32 
27 
24 
NA 
NA 
NA 
17 
46 
Ρ 
NS 
NS 
NS 
0.03 
NS 
NS 
NS 
0.05 
NS 
Ref. 
148 
149 
150 
151 
152 
153 
154 
155 
156 
Abbreviations: A = adriamycin, В = BCNU, С = cyclophosphamide, 
Cyt = cytarabine, E* = etoposide, F = 5-fluorouracil, I = ifosfamide, 
L = leucovorin, M = mitomycin-C, Me = methyl-CCNU, MTX = methotrexate, 
Tri = triazinate, VCR = vincristine, NA = Not Available, NS = not significant 
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Preoperative chemotherapy 
To date, preoperative or neoadjuvant chemotherapy seems the most promising 
approach to increase the rate of curative resections in patients with gastric cancer 
by eradication of micrometastases early after diagnosis. In addition, reduction in 
tumor size could have an impact on resection rates (down-staging). A number of 
phase II trials have been performed investigating the ability of preoperative 
chemotherapy to influence outcome in patients with gastric cancer. In assessing 
these trials, one should be careful to separate studies in which patients who had 
potentially resectable gastric cancer at diagnosis underwent surgery after 
receiving chemotherapy, from studies in which patients with unresectable locally 
advanced gastric cancer received similar treatment. 
Table 5 summarizes trials in which it was shown that locally advanced and not 
resectable tumors as defined by explorative laparotomy could be rendered 
resectable by preoperative chemotherapy. In a trial of Wilke et a/.39, who used 
preoperative EAP in 33 évaluable patients with irresectable gastric cancer, 20 of 
23 patients who had an objective response to chemotherapy underwent a second 
look operation. In 15 patients the tumor had become resectable. In this study a 
median survival time for all patients of 18 months and for disease-free patients 
of 24 months was achieved, whereas in untreated patients a median survival of 
3 - 5 months can be expected. 
A positive impact on prognosis was also claimed in studies were preoperative 
chemotherapy was given to patients with clinically staged locally advanced 
disease (Table 6). However, the difficulty with this approach is the lack of reliable 
criteria for clinically defining locally advanced disease. The other difficulty is that 
in these studies no randomization to a no-treatment arm was performed, thus 
interpretation of results would rely only on historical controls. 
In an interim report, Kang er a/.40 presented the preliminary results of a study 
comparing preoperative chemotherapy (cisplatin plus etoposide plus continuous 
infusion of 5-FU) followed by surgery with surgery alone in clinically staged locally 
advanced gastric cancer. At the time of their preliminary report, 51 patients had 
entered the study. Curative resections were possible in 75% of patients in the 
neoadjuvant arm and 56% in the surgery arm. Twenty-five percent of patients had 
stage IB or less in the neoadjuvant arm, while no early stage tumors were seen 
in the surgery only arm. Based on these results the authors continue patient 
accrual. 
In summary, in assessing results of trials of neo-adjuvant chemotherapy in gastric 
cancer, one has to take in mind that patients with potentially resectable tumors 
at the time of study entry are different from those with advanced unresectable 
disease, who only undergo exploration if they have response. The currently 
available data indicate that neoadjuvant chemotherapy is feasible and that the 
results are encouraging. Therefore it may be proposed to patients with locally 
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Table 5 
Results of preoperative chemotherapy in unresectable gastric cancer at prior laparotomy. 
Treatment 
E*AP 
E*EP 
FMTX 
E*AP 
pre + post 
pre 
pre 
pre 
33 
19 
17 
41 
23 
8 
8 
NA 
20 
10 
14 
37 
15 
7 
8 
32 
5 
0 
0 
0 
18 
NA 
NA 
NA 
Timing of No. Responses No. of Complete Pathologic Median Ref. 
chemotherapy of (CR + PR) patients resection complete survival 
évaluable having achieved response (months) 
patients surgery 
39 
157 
15Θ 
159 
Abbreviations: A = adriamycin, E* = etoposide, E = epirubicin, F = 5-fluorouracil, MTX = methotrexate, Ρ = cisplatin, 
NA = Not Available 
Table 6 
Results of preoperative chemotherapy in potentially resectable gastric cancer. 
Treatment Timing of No. Responses No. of 
chemotherapy of (CR + PR) patients 
évaluable having 
patients surgery 
Complete Pathologic Median 
resection complete survival 
achieved response (months) 
Ref. 
Ю 
00 
E*FP 
FLP + floxuridine 
+ Ρ i.p. 
E'AP 
FP 
E*FP 
E*AP + G-CSF 
FAMTX + 
Ρ i.p. + Fi.v 
pre + post 
pre + post 
pre + post 
pre + post 
pre 
pre 
pre + post 
25 
38 
48 
27 
24 
30 
46 
6 
17 
15 
15 
NA 
NA 
NA 
25 
35 
41 
27 
20 
30 
37 
18 
29 
37 
17 
15 
24 
23 
0 
1 
0 
0 
3 
NA 
NA 
15 
17+ 
16 
16 
NA 
16 
NA 
160 
161 
162 
163 
40 
164 
165 
Abbreviations: A=adriamycin, E=epirubicin, E* = etoposide, F=5-fluorouracil, G-CSF=filgastrim, MTX= methotrexate, 
Ρ = cisplatin, i.p. = intraperitoneal, i.v. = intravenous, NA = Not Available 
Chemotherapy of gastric cancer 
advanced gastric carcinomas, if they have an unresectable gastric cancer at prior 
laparotomy. For patients with potentially resectable locally advanced cancer only 
randomized studies comparing preoperative chemotherapy versus initial surgery 
can be recommended. 
Conclusion 
Gastric canceris a chemotherapy-sensitive neoplasm. With the new combination 
cytotoxic regimens approximately half of the patients with metastasized disease 
may benefit from chemotherapy by reduction of tumor-related symptoms and/or 
prolongation of survival. 
The resultsof trials with adjuvant chemotherapy of gastric cancer are disappointing. 
Furtherwell designed trialswith new and more active chemotherapy regimens are 
needed. Atthismomentadjuvant chemotherapy is notindicated outside of clinical 
trials. 
Neoadjuvant chemotherapy has been studied in an attempt to improve relapse-
free survival and cure rate in patients with locally advanced disease. There have 
been promising results, but large-scale confirmatory studies and prospective 
randomized trials are needed in order to establish the role of this treatment 
modality. Furthermore, new developed drugs such as taxotere and irinotecan 
have to be incorporated in new chemotherapy regimens. 
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Summary 
Cytosolic glutathione S-transferases are a family of enzymes involved in the 
metabolism of drugs, toxins, carcinogens and also of anticancer drugs. Recent 
studies have indicated that glutathione S-transferases (GSTs) may play an 
important role in the resistance of cells to toxins and carcinogens but also to 
anticancer drugs. 
This report reviews the current literature concerning the role of glutathione S-
transferases in anticancer drug resistance. Moreover, the significance of GST Pi 
in carcinogenesis and its role as prognostic factor is discussed. 
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Introduction 
The effectiveness of many clinically useful anticancer drugs can be severely 
limited by drug resistance, which appears to be intrinsic to some tumors but can 
also arise during multiple courses of chemotherapy. Studies carried out using 
cultured tumor cell models have established that a variety of mechanisms can 
contribute to drug resistance. These include alterations in drug uptake or drug 
efflux from the cell (e.g. P-glycoprotein), changes in drug metabolizing enzymes 
(glutathiones-transferases), changes intarget enzymes (dihydrofolate reductase) 
and in enzymes of DNA repair (06-methylguanine alkyltransferase). Acquired 
resistance to chemotherapeutic drugs typically involves several independent 
mechanisms. 
As part of their normal diet or living environment all organisms are constantly 
exposed to harmful chemicals (xenobiotics). Consequently, the development of 
protection mechanisms against the possible damage imposed by exposure to 
xenobiotics has been an essential part of the evolutionary process1. The 
glutathione S-transferases (GSTs) constitute a remarkably versatile family of 
enzymes involved in the cellular detoxification of xenobiotics. These enzymes 
have in common the ability to catalyze the conjugation of various electrophilic 
compounds with glutathione (GSH), a reaction which detoxifies compounds by 
covalent attachment of glutathione to the potentially harmful electrophilic 
compounds. Hydrophobic toxins conjugated with glutathione also become more 
water-soluble and thus are more readily excreted from cells. GSTs also protect 
cells by sequestering toxins through high-affinity binding and by preventing 
oxidative damage through intrinsic organic glutathione peroxidase activity. The 
role of GSTs in protecting healthy cells from cytotoxic insult is well-established2. 
There is increasing evidence that malignant cells may also be capable of using 
these enzymes for protection against cytotoxic agents, by readily inactivating 
them. 
Properties of GSTs 
Many molecular forms of GST have been identified from various organs in a 
variety of species". The various human cytosolic GST isoenzymes have been 
divided into four classes: Alpha, Mu, Pi and Theta". Each GST class has distinct 
but overlapping substrate specificity. 
The cytosolicGSTs aredimeric proteins consisting of two subunits of approximately 
25 kD molecular mass (range 23 - 28 kD). The isoenzymes are homodimers, 
consisting of identical subunits, orheterodimers, consisting of different subunits910. 
GSTs have in common the ability to catalyze the conjugation of diverse 
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electrophilic compounds with GSH, a reaction which detoxifies compounds by 
covalent attachment of GSH to potentially harmful electrophilic groups. GSTs 
also protect cells by sequestering toxins through high-affinity binding and by 
preventing oxidative damage through intrinsic organic peroxidase activity2. 
The distribution of GST isoenzymes is tissue specific. GST class Alpha is mainly 
expressed in the liver, kidney and small intestine1013, while GST Pi is expressed 
as a major form in many organs such as lung, breast, large intestine or urine 
bladder1315. The reasons for this specific expression of GST isoenzymes among 
different tissues most likely reflects the need to deal with specific substrates, 
which considerably varies between organs. The Mu and Theta class of GSTs 
appears to be expressed at relatively low levels in many organs. However 
polymorphism in the Mu and Theta gene have been reported, and GST-M1 levels 
cannot be detected in approximately 50% of the Caucasians tested141618, 
whereas GST-T1 is absent in about 15% of the Caucasians. These percentages 
vary greatly between the different human races2. The expression of GST forms 
is not only tissue specific, but also regulated by development. Developmental 
change in expression of GST Alpha as well as GST Pi have also been noted in 
several tissues19 22. For example, GST Pi is not expressed in adult liver, except 
in biliary epithelium, but is expressed in large amounts in fetal liver2324. 
Transport of glutathione conjugates 
It is important for cells to eliminate conjugates efficiently, since many GSH-
conjugates are potential inhibitors of GSTs and other GSH-associated enzymes. 
In addition, the conjugates may retain some cytotoxicity, so their efficient removal 
may be beneficial for the survival of the cell. 
Several transport systems have been described, including a Na+-dependent 
transporter, localised in the basolateral membrane of kidney and intestinal cells, 
and a Na+-independent transporter, localised in the brush borders of enterocytes 
and in the basolateral and cannicular membranes of liver cells25. More recently, 
an efflux system has been described for GSH-conjugate removal, the ATP-
dependent GSH-xenobiotic (GSH-X) pump26. There is increasing evidence that 
the multidrug resistance associated protein (MRP), which is often overexpressed 
in tumor cells resistantto anticancer drugs, may be identical or at least very similar 
to the GSH-X pump25. 
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GSTs in carcinogenesis 
An important finding was the discovery of changes in GST isoenzymes dunng the 
process of malignant transformation in some model systems of chemical 
carcinogenesis A number of studies have shown that dunng malignant 
transformation of rat hepatocytes following exposure to carcinogens, there is 
increased expression of a number of GST isoenzymes27 2B Of particular interest 
was the dramatic increase in the concentration of GST Pi, which normally is 
present at very low levels in adult rat hepatocytes29 Increased expression of GST 
Pi has also been found in many human tumors1315 х 31 The biological significance 
of these findings is still unclear, but they do suggest that increased expression of 
GST Pi may be a marker of malignant transformation of liver cells 
There is increasing evidence that high GST Pi expression may be a marker for 
certain phenotypes arising from malignant transformation, which are generally 
biologically agressive phenotypes High GST Pi expression was negatively 
correlated with survival in patients with colorectal tumors32 or renal cell carcinomas33, 
and with pathologically-defined biologically-aggressive features in human soft 
tissue sarcomas34 In a study from Gilbert era/ ^, high expression of GST Pi was 
a strong predictor of relapse and death in the subgroup of women with axillary 
node-negative breast cancer, none of whom had received chemotherapy prior to 
relapse These data suggest a possible relationship between high GST Pi 
expression and bad prognosis 
GST expression and cellular resistance 
GSTs protect cells from environmental toxins Anticancer drugs also can be 
considered as xenobiotic toxins and therefore much effort has been devoted to 
examine the conjugation of antineoplastic agents and their active metabolites 
withGSH There is much evidence that alkylating agents (e g cyclophosphamide 
and melphalan), antimetabolites (e g azathiopnne), platinum compounds (e g 
cisplatm), and drugs such as adriamycin can be conjugated with GSH, catalyzed 
by GSTs2 25 36 In several studies overexpression of GST was found in a variety 
of human and rodent cell lines, which display different intrinsic levels of resistance 
to cytostatic drugs The majority of these resistant lines contained elevated levels 
of GST class Pi2 37 38 However, cell lines selected for drug resistance often display 
multiple phenotypic changes, making it difficult to find a direct causal relationship 
between a single biochemical vanable and the global transformation of the 
sensitive cell line into a resistant one In order to examine the isolated effects of 
increased expression of individual GST isoenzymes, several laboratories have 
performed gene transfection experiments MCF-7 human breast cancer cells 
50 
Glutathione S-transferases and cancer 
were stably transfected with expression vectors containing GST class Pi39, class 
Mu40 and class Alpha40 41 In each of the clones transfected, the increased levels 
of GST isoenzyme failed to confer significant levels of resistance to any of the 
antmeoplasticdrugstested However, Puchalskiand Fahl42 transfected expression 
vectors forGST Alpha, Mu and Pi into monkey kidney COS cells Transfected cells 
were subsequently found to contain increased GST activity, and these cells were 
also shown to be more resistant to several cytotoxic agents (doxorubicin, 
melphalan, chlorambucil), when compared to non-transfected cells 
In addition to mammalian cell lines, the effect of transfection of GST Pi and Alpha 
into the yeast Saccharomyces Cerevisiae was examined43 Since yeast can be 
transfected with great efficiency, the GST transfected yeast contained very high 
levels of GST Transfected cells were subsequently found to have a significant 
reduced susceptibility for the cytotoxic effects of doxorubicin or chlorambucil 
Maximal resistance in the yeast system was 16-fold for doxorubicin and 8-fold for 
chlorambucil 
The relation between GSTs and drug resistance may be of clinical relevance 
Total GST activity44 and specific expression of GST Pi45 showed a correlation with 
clinical response in two studies of patients with leukemia However, in another 
study of patients with leukemia there was no correlation between GST activity and 
response to chemotherapy46 Three studies in patients with ovanan tumors 
indicated that a low level of GST Pi was prognostic for response to chemotherapy 
and prolonged survival47"19 In contrast, GST activity and isoenzyme distribution, 
or immunostaming of GST Pi did not predict response to chemotherapy in four 
other senes of patients with ovarian cancer50 53 In two studies, concerning node-
positive breast cancer patients treated with adjuvant chemotherapy, the 
pretreatment expression levels of GSTs had no predictive value54 55 Furthermore 
in human soft tissue sarcomas no correlation was found between GST Pi 
expression and response to chemotherapy34 
Based on these preclinical and clinical studies it can be said that the role of GST 
in prognosis or anticancer drug resistance is controversally However, it should 
be considered that most of the clinical studies only contained a small number of 
patients Furthermore, in above mentioned studies the role of GSTs was 
examined using different chemotherapy regimens, so the results can not be 
compared easily 
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Conclusions 
GSTs play an important role in cellular protection against chemical and oxidative 
stress. The GST isoenzymes are divided into four classes, each consisting of one 
or more isoenzymes. Each GST isoenzyme has distinct but partially overlapping 
substrate specificities. These enzymes are able to catalyze the conjugation of a 
broad range of substrates, including some anticancer drugs. Elevated levels of 
certain GST isoenzymesare associated with malignanttransformation. Increased 
GST activity is observed in many models of drug resistance, but it is not known 
whether this reflects a nonspecific reaction or whether GSTs have a specific role 
of utmost clinical relevance in this process. 
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Summary 
Cell kinetic data may be important indicators of clinical behavior in many types of 
cancer. Recently, several antibodies to cell-cycle associated antigens have been 
characterized. 
This overview summarizes the advantages and disadvantages of different 
methods for assessment of cell proliferation. Moreover, the prognostic value of 
proliferative activity in gastric cancer is discussed, and suggestions for future 
research are given. 
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Introduction 
The cell cycle 
The basic concept of the cell cycle is demonstrated in Figure 1. In a replicating 
eukaryotic cell the life-cycle can be divided into four main phases, and the 
transition from one phase to another phase in the cell cycle is probably thightly 
controlled. DNA synthesis and doubling of the genome take place during the 
synthetic or S-phase. This is preceded by a period of variable duration known as 
the first gap (G,) which separates the S-phase from the previous mitosis (M-
phase). The S-phase is followed by a period of apparent inactivity known as the 
second gap (G2) which comes before the next mitosis. Another phase can be 
discerned, being the G0 or resting phase, in which cells are no part of the cell cycle 
but, after suitable stimuli, may rejoin the cycling population1. In normal tissue and 
probably also to some extent in tumors, there is a balance between cell birth and 
cell loss. Differentiation and apoptosis lead to cell death and are important forthe 
balance between cell growth and cell death. In any tissue there are also cells that, 
for whatever reason, are no longer able to divide and so any cell population can 
be divided into a cycling and a non-cycling compartment. This leads to the 
definition of the proliferative fraction of any cellular population as the ratio of 
cycling to cycling plus non-cycling cells (cycling cells/total cells)2. 
Figure 1 
The concept of the cell cycle 
Apoptosis 
ж 
f Differentiation 
Go 
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Methods for asssessing cell proliferation 
There is a correlation between the proliferation rates (the ratio of cycling cells/total 
cells in the population) of certain tumors and their biologic behavior. Various 
methods are widely used to measure the percentage of proliferating cells. In 
gastric cancer, as well as in other cancers, measurements of proliferative activity 
have been performed by different methods. However, each method has some 
practical problems for routine pathology. The most important methods for 
determination of proliferative activity are described here. A summary of these 
methods is listed in Table 1. 
Mitotic count 
The mitotic count is perhaps the most convenient and therefore the most widely 
used method for assessment of cellular proliferation. It is defined as the number 
of mitosis per ten high-power fields (HPFs). It is important to distinguish this from 
the mitotic index, which is the fraction of mitoses expressed as percentage. The 
mitotic count has long been employed by histopathologists as a diagnosticaid and 
a prognostic indicator in the study of tumor pathology. Despite this, the validity of 
the mitotic count as a marker of tumor proliferative activity remains controversial. 
It is not a standardised method3 4; it takes no account of cell size5·6 and the area 
of a single HPF may vary up to six-fold between different microscopes7. The 
mitotic count is also subject to inter-observer variation8. 
Despite these obvious limitations it is widely used in clinical practice, and it can 
serve as a first impression of proliferative activity. 
Thymidine labelling 
The first wave of cell kineticinvestigations in man was started afterthe introduction 
of techniques using incorporation of tritiated thymidine into the cellular DNA. Only 
cells that are actively synthesizing DNA (S-phase cells) will incorporate tritiated 
thymidine during a short time exposure (pulse-labelling). These cells can be 
detected using autoradiography. Therefore, pulse-labelling with tritiated thymidine 
is regarded as a functional marker of proliferative activity, reflecting the fraction 
of S-phase cells. Determination of thymidine labelling requires the in vivo 
administration of radiolabelled thymidine which can rarely be justified in clinical 
practice. Alternatively, tissue must be incubated with tritiated thymidine for some 
time in vitro before fixation. Both of these restraints militate against thymidine 
labelling as a practical routine procedure for histopathologists. The use of 
thymidine labelling indexas an indicator of tumor proliferative activity has several 
other limitations. Firstly, it documents number of cells in the S-phase, but does 
not measure the duration of the S-phase. It is thus possible for a tumor to have 
a slow rate of cell proliferation and a high thymidine labelling index9. Secondly, 
tumors may display heterogenous growth patterns and it is argued that a method 
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which relies upon a sample from a part of the tumor can be, at best, only a crude 
index of the proliferative capacity of that tumor10. Thirdly, as with any technique 
which involves cell counting, human inter-observer variation, reproducibility error 
and sample size may produce misleading results. Finally, measurement of 
thymidine labelling index requires fresh tissue, is time-consuming, necessitates 
autoradiography, and is not a readily available technique for routine laboratory 
services. Nevertheless for many years this was the only reliable method available 
for assessing cell proliferation, and the data based on this method and reported 
in many studies have been pivotal for the development of our understanding of 
tumor growth11. 
DNA flow cytometry 
Flow cytometry (FCM) is an automated technique which quantifies cellular DNA 
content and analyses cell cycle distribution12. A cell suspension, prepared from 
a tissue sample, is stained with DNA-specif icfluorochrome dyes. The suspension 
then flows through a light source with stationary fluorescence detectors, at a rate 
of about 5000 cells per second. The light scattered by the cells is registered by 
the detectors and converted into electronicsignals which are stored and analysed 
by computer. The computer produces a DNA histogram from which a number of 
data can be derived. The cellular DNA content, known as its ploidy status, is 
expressed as the DNA index. This is the ratio of the G0/G1 cells of the population 
being studied to that of an internal or external standard diploid cell population. A 
diploid cell has a DNA index of 1.00. Cells with an index of 2.00 are tetraploid, and 
greaterthan2.00 aneuploidorpolyploid. The S-phase content and the proliferative 
activity (S+G2M phases) can also be determined by deconvoluting the DNA 
histogram. The technique can be applied to paraffin-embedded material as well 
as to fresh tissue13. FCM has the advantage of speed and statistical precision. 
Typically 10,000 -100,000 cells or nuclei can be scanned in a few minutes or less. 
Multiple parameters can be measured simultaneously on individual cells; this can 
be a useful attribute of the technique. An important disadvantage of FCM is that 
very expensive apparatus is required. In addition, when studying solid tissues, the 
need to disaggregate the tissue into a suspension of single cells or nuclei can be 
a problem. Some solid tissues are difficult to disaggregate, and in all cases tissue 
morphology is lost. 
lododeoxyuridine or Bromodeoxyuridine labelling 
Measurement of a kinetic cell profile (including data on the duration of cell cycle 
phases) has become feasible through the introduction of techniques using in vivo 
incorporation of lododeoxyuridine (IdU) or Bromodeoxyurine (BrdU). IdU and 
BrdU are pyrimidine analogues which are incorporated by DNA-synthesizing 
nuclei. IdU or BrdU containing cells are detected with monoclonal antibodies1416. 
After additional staining the total cell population with propidium iodide (which 
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stoichiometrically intercalates into DNA), simultaneously the proportion of BrdU/ 
IdU labelled cells and their total DNA content can be measured by flow 
cytometry17. From these measurements both the labelling index and the DNA 
synthesis time can be determined on a single tumor sample. Other cell kinetic 
parameters such as the potential tumor doubling time can then be mathematically 
derived. 
Flow cytometric analysis of IdU or BrdU incorporation provides cell kinetic 
information on human tumors, which can not readily be obtained by other 
methods. However, it provides "averaged" values and sacrifices information on 
the tissue spatial distribution of proliferation as a consequence of the prerequisite 
of a single cell or nuclei suspension. Nevertheless, because IdU or BrdU are 
administered in vivo, the application of immunoperoxidase techniques can be 
applied to study proliferation at the microscopic level. Immunohistochemical 
determination of IdU or BrdU provides information on heterogeneity and structural 
organisation of proliferation. 
Proliferating cell nuclear antigen 
Proliferating cell nuclear antigen (PCNA) is a 36 kDa nuclear protein, which 
functions as an auxiliary protein for DNA polymerase Delta and is an absolute 
requirement for DNA-synthesis1823. It is a stable cell-cycle-regulated nuclear 
protein that is expressed differentially during the cell cycle and whose rate of 
synthesis is correlated directly with the proliferative rate of cells. During the cell 
cycle, two populations of PCNA can be distinguished. Using immunofluorescent 
methods, Bravo and co-workers24 showed that one population is nucleoplasms, 
corresponding to PCNA present at low levels, as seen in quiescent cells capable 
of cell division. The second form of PCNA was associated with specific nuclear 
structures, tightly associated to sites of DNA replication, and was thought to play 
a fundamental role in eukaryotic DNA synthesis. Expression of this form is closely 
related to the cell cycle; the levels of PCNA increase in the nucleus during the late 
G^phase, immediately before the onset of DNA synthesis, become maximal 
during the S-phase, decline during the G2-phase, and reach a low level in the M-
phase and quiescent cells23. A wide range of monoclonal antibodies to PCNA are 
available now, including PC10, 19A2 and 19F4. The epitopes recognized by 
these antibodies are different25 and there are differences in the effects of fixation 
and processing on the detectability of the epitopes26, indicating that the effect of 
technical factors on PCNA staining should not be underestimated. Furthermore, 
since PCNA is a necessary but not sufficient requirement of DNA synthesis, it may 
be expressed by cells that are not cycling. So the use of PCNA antibodies is not 
simple and straightforward but requires careful analysis and consideration of all 
these caveats. 
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Table I 
Methods for detection of proliferating cells 
Mitotic count 
Material 
Phase 
Advantage 
Disadvantage 
Fixed 
M-phase 
Simple 
Identification of mitosis is difficult; Method is not standardised; 
Inter-observer variation 
Thymidine labelling 
Material 
Phase 
Advantage 
Disadvantage 
Flow cytometry 
Material 
Phase 
Advantage 
Disadvantage 
Fresh 
S-phase 
None 
In vivo administration of radiolabelled thymidine (or alternatively 
specimens must be incubated with thymidine in vitro before 
fixation); Time consuming 
Fresh or fixed 
S, G2 and M-phase 
Large number of cells can be analysed 
Expensive equipment; Need to disaggregate tissues into a 
suspension of single cells 
Bromodeoxyuridine or lododeoxyuridine labelling 
Material Fresh or fixed 
Phase S-phase 
Advantage Information about cell kinetics 
Disadvantage In vivo administration of Bromodeoxyuridine or lododoxyuridine 
(or alternatively specimens must be incubated with 
Bromodeoxyuridine or lododeoxyuridine in vitro before fixation) 
PCNA 
Material Fixed 
Phase Gv G S and M-phase 
Advantage Simple 
Disadvantage Expression is dependent of kind and duration of fixation 
Fresh 
Ki-67 
Material 
Phase 
Advantage 
Disadvantage Need for fresh or snap-frozen material 
Gv G , S and M-phase 
Simple 
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Table I (continued) 
MIB-1 
Material Fixed 
Phase G,,G S and M-phase 
Advantage Simpfe 
Disadvantage More extensive research is needed to evaluate the role of this 
relatively new antibody 
AgNOR 
Material Fixed 
Phase Unknown 
Advantage Simple 
Disadvantage AgNOR counts are influenced by otherfactors such as variations 
in ploidy 
Ki-67 
Ki-67 is a mouse monoclonal antibody that identifies a nuclearantigen associated 
with the cell cycle27. Detailed cell cycle analysis has demonstrated that the Ki-67 
antigen is expressed in all phases except G0 and early G,28. Thus Ki-67 
immunostaining provides a measure of the tumor proliferative fraction. The 
epitope recognized by Ki-67 does not survive formalin fixation and paraffin 
embedding. So, the requirement of fresh tissue for cryostat sections is a major 
obstacle to the routine use of Ki-67. 
MIB-1 
MIB-1 is a relatively new, but promising, antibody for determination of the 
proliferative fraction of tumorcell populations. Itwas developed using a recombinant 
partial structure of the Ki-67 protein as immunogen. MIB-1 exhibits an identical 
immunostaining pattern to that of Ki-67 in fresh material and furthermore reacts 
with the native Ki-67 protein as well as with recombinant parts of the Ki-67 
antigen29. MIB-1 can detect the Ki-67 protein in routinely formalin fixed paraffin 
wax embedded material when using an antigen retrieval method, based on 
microwave treatment30·31. 
The use of MIB-1 for determination of cell proliferation has several obvious 
advantages. First, the combination of strong immunoreactivity with an optimal 
preserved morphology allows a good recognition of cellular details and therefore 
a better identification of positive cellular subsets. Second, the neat and clear 
immunoreaction products allow a clear-cut distinction between positive and 
negative cells even if only minute amounts of antigen are stained. A third 
advantage of this method is that it can be applied in virtually every histopathological 
laboratory all over the world, since no sophisticated technical skill is needed. 
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Table 2 
Comparison between different proliferation markers 
Comparison 
In vivo BrdU versus 
Thymidine 
DNA ploidy 
Ki-67 
MIB-1 
AgNOR 
In vitro BrdU versus 
PCNA 
Ki-67 
MIB-1 
PCNA versus 
S-phase fraction (FCM) 
S + G2M phase fraction (FCM) 
DNA ploidy (FCM) 
Ki-67 
MIB-1 
Tumor/Tissue 
Colorectal tumors 
Gastric cancer 
Cerebral gliomas 
Cerebral gliomas 
Brain tumors 
Cerebral gliomas 
Cerebral gliomas 
Cerebral gliomas 
Brain tumors 
Gastric cancer 
Gastric cancer 
Gastric cancer 
Gastric mucosa 
Brain tumors 
Bladder carcinoma 
Brain tumors 
Gastric mucosa 
Brain tumors 
Breast carcinoma 
Astrocytoma 
Non Hodgkin's lymphoma 
Gastric cancer 
Lung cancer 
Brain tumors 
Non Hodgkin's lymphoma 
Breast carcinoma 
Breast carcinoma 
Prostatic carcinoma 
Brain tumors 
Astrocytoma 
Non Hodgkin's lymphoma 
Breast carcinoma 
Prostatic carcinoma 
Testis carcinoma 
Normal bone marrow 
Significant 
correlation 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
No 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Ref. 
50 
36 
51 
52 
53 
51 
52 
52 
53 
33 
34 
35 
38 
54 
55 
54 
38 
54 
56 
57 
58 
37 
59 
54 
22 
56 
60 
61 
54 
57 
5B 
56 
61 
62 
63 
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Table 2 (continued) 
Comparison 
Ki-67 versus 
S-phase fraction (FCM) 
MIB-1 
AgNOR 
MIB-1 versus 
S-phase fraction (FCM) 
S + G2M phase fraction (FCM) 
Tumor/Tissue 
Non Hodgkin's lymphoma 
Breast carcinoma 
Brain tumors 
Cerebral gliomas 
Cerebral gliomas 
Non Hodgkin's lymphoma 
Breast carcinoma 
Breast carcinoma 
Prostatic carcinoma 
Brain tumors 
Astrocytoma 
Non Hodgkin's lymphoma 
Breast carcinoma 
Breast carcinoma 
Astrocytoma 
Breast carcinoma 
Significant 
correlation 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
No 
Yes 
Ref. 
58 
56 
54 
51 
53 
58 
56 
65 
61 
53 
57 
58 
65 
56 
57 
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Nucleolar organizer regions 
Nucleolar organizer regions (NORs) are DNA segments encoding for ribosomal 
RNA32. They can be visualized because each NOR is associated with argyrophilic 
proteins; the silver-stained structures thus demonstrated are called AgNORs. 
Several studies show that there is a correlation between Ag NOR counts and other 
cell proliferation indices. However, AgNOR counts may not be a perfectly reliable 
paradigm for other measures of proliferative activity because the counts are 
influenced by otherfactors such as variations in ploidy and transcriptional activity. 
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Comparison of different methods for measurement of cell proliferation 
Several studies compared different methods of determination of proliferation, a 
summary is given in Table 2. 
In gastric cancera significant correlation was found between in vitro BrdU labelling 
index (LI) and PCNA LI3335, between in vivo BrdU LI and DNA ploidy36, whereas 
no significant correlation was found between PCNA LI and S + G2M-phase 
fraction measured by flow cytometric analysis37. Lynch et a/.38 described a 
significant correlation between in vitro BrdU LI and MIB-1 LI in normal gastric 
tissue, but not between in vitro BrdU LI and PCNA LI. 
Although many proliferation markers are compared, both in gastric carcinomas 
and in other tumors, results fom comparative studies are often contradictory. 
However it must be taken in mind that these studies are not completely 
comparable, because of differences in fixation method, fixation time or the use 
of different antibodies. 
Cell proliferation in gastric tissue 
Cell proliferation in normal gastric mucosa 
In normal gastric mucosa the proliferative zone is located in the neck of the gastric 
gland39. From this region newborn cells migrate towards the surface and, to a 
lesser extent, towards the bottom of the gland. The downward migration seems 
to be more complex than that towards the surface40. During their migration, the 
cells loose their proliferative activity and become mature elements: mucous cells 
if they go upwards or parietal cells if they go downwards. Peptic zymogen cells 
seem to have an autonomous replication cycle41. 
Cell proliferation abnormalities in premalignant gastric conditions 
In animal studies it was shown that chemical carcinogens stimulate cell renewal42. 
In man certain conditions at risk for gastric cancer showed an increased cell 
proliferation rate. In chronic atrophic gastritis the number of proliferating cells was 
increased as compared to controls43^6. Higher proliferation rates were also 
observed in patients with intestinal metaplasia45 46, Helicobacterpylori associated 
gastritis45·47-48, gastric dysplasia49 and in patients with gastric remnant resections48. 
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Cell proliferation as prognostic marker in gastric cancer 
Information of cell proliferation may be a useful adjunct to histologically based 
tumor classifications in the understanding of tumor behavior. In a variety of 
malignant neoplasms significant correlations were found between proliferative 
activity and metastatic potential, recurrence or overall prognosis22. In particular 
during the lastfewyears, several studies consistently investigated the prognostic 
relevance of cell proliferative activity in gastric cancer. The resultsof these studies 
are summarized in Table III. In evaluating these studies one should keep in mind 
that differences in number of patients included, presentation of the results, and 
most importantly, the way in which the patients were treated make direct 
comparisons of these studies difficult. 
Studies, evaluating the prognostic significance of thymidine labelling in gastric 
cancer, showed contradictory results. Amadori et al.67 determined the in vitro 
thymidine labelling index in endoscopic biopsies of 28 patients with gastric 
cancer. In this small study the 3-year survival was significantly higher in patients 
with slowly proliferating tumors. However, in a second study68 the same authors 
studied the prognostic significance of c-myc, c-K-ras, hst, c-erb B-2 gene 
amplification and of thymidine LI in gastric cancer. The oncogenes were 
determined in 124 tumor samples from patients who had received radical or 
palliative surgery for gastric cancer, whereas thymidine LI was determined in 70 
tumor specimens. They found that amplification of the examined oncogenes and 
determination of thymidine LI did not reveal a new independent prognostic factor. 
In a study by Tanigawa et al.69 the prognostic value of tritiated thymidine uptake 
in 173 patients with gastric cancer was evaluated. In this prospective study the 
thymidine uptake was found to be an independent prognostic parameter. 
The prognostic value of DNA flow cytometry in gastric cancer was determined in 
7 studies. In three retrospective studies flow cytometric analyses of DNA ploidy 
patterns was performed in deparaffinized formalin-fixed gastric cancer tissue. 
Tosi et al.70 examined 133 samples and in accordance with the results of Danova 
et al.71 (42 patients) an aneuploid DNA pattern was associated with poorer 
prognosis. In contrast, Ballantyne et al.72 failed to find any significant correlation 
between DNA ploidy, tumor type or survival after investigation of 77 samples. 
In a prospective study Sasaki et al.73 investigated the relationship of DNA ploidy 
(determined in fresh material) to clinical, pathological and prognostic data. In their 
study of 70 patients, patients with diploid tumors tended to do better than these 
with aneuploid tumors, but the difference was not statistically significant. 
The prognostic value of DNA ploidy pattern and proliferative activity after in vivo 
administration of bromodeoxyuridine was examined in large groups of patients 
by Ohyama et al.74 and Yonemura et al.75, showing that patients with aneuploid 
tumors or with tumors who showed greater proliferative activity had a poor 
71 
Chapter 4 
prognosis. In a second study, Ohyama et al.76 examined the prognostic values 
of BrdU LI and DNA index and found that the ratio of BrdU LI to DNA index was 
the most accurate reflection of the proliferation rate. Again, patients with a high 
proliferation rate had a worse prognosis. 
In conclusion, 5 out of 7 studies found a significant correlation between DNA 
ploidy and survival, indicating thatthis method provides prognostic information on 
gastric cancer. 
Yonemura et al.77 also studied the prognostic significance of proliferative activity, 
as measured by immunohistochemistry after in vitro BrdU labelling. In this study 
BrdU LI was an independent prognostic parameter. 
Analysis of proliferative activity using PCNA was performed in five studies. All 
used the PC10 antibody. In 4 studies33 35 M 78 PCNA LI emerged as an independant 
prognostic factor, whereas a relatively small study of Jain et al.37 failed to show 
a significant correlation between PCNA LI and survival. However unlike the PCNA 
LI, semiquantitative PCNA grading seemed to be a good predictor of prognosis 
with significant differences between low and high PCNA grade groups. In the 
study of Kakeji et al.64 proliferative activity was investigated using PCNA and 
AgNOR count. A significant correlation was found between PCNA LI and AgNOR 
count. However, in a multivariate regression analysis only the PCNA LI was an 
independent prognostic parameter. So, the present data clearly suggest that the 
PCNA LI represents an useful prognostic factor in gastric cancer. 
In just one study79 the prognostic role of MIB-1 LI in gastric cancer was examined. 
No significant correlation could be demonstrated between MIB-1 LI and survival. 
The results of above mentioned studies assessing cellular proliferation in gastric 
cancer are sometimes contradictory, and a variety of methods was used to 
measure the proliferative fraction. However there is considerable evidence that 
assessment of proliferation provides useful information with respect to prognosis 
for gastric cancer. Multivariate analyses should be performed to establish which 
method is best to be used. 
Conclusions 
There is considerable evidence that assessing cellular proliferation in a variety of 
tumors, including gastric cancer, provides useful information and may be of 
prognostic importance. In the next future, multivariate analyses should be 
performed to establish which method should preferably be applied in order to 
obtain accurate data on cell proliferation in gastric cancer. 
In this review a variety of methods for determination of cellular proliferation are 
described. Each of the described techniques has limitations, and at this moment 
it is not completely clear what is the best method for assessment of proliferation. 
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Ideally such a method should be simple, inexpensive and reproducible. For 
widespread use it is necessary that it is applicable to conventionally processed 
histological and cytological preparations. An important advantage of the use of 
MIB-1 for determination of cell proliferation is that this method is very simple and 
can be applied on routinely processed tissue in virtually every histopathological 
laboratory all over the world. However, its role as prognostic factor in gastric 
cancer is still unclear, and more research is needed to evaluate the role of MIB-
1 in gastric cancer and to unravel the interrelationships between MIB-1 and other 
methods of determining cellular proliferation. 
Until now, little attention has been paid to the relationship between tumor 
proliferation and response to treatment. The hypothesis that assessment of 
cellular proliferation during and aftertreatment may give clinically useful information 
about response should be considered, especially in patients treated with 
cytostatic drugs. In this respect it should be studied first whether there are 
differences between fast and slow proliferating tumors, and whether cytostatic 
drugs can induce changes in the proliferative activity. Another main area of future 
research is to investigate the value of cellular proliferation in premalignant 
conditions. 
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Table 3 
Correlation between patient's survival and cell proliferation rate in gastric 
cancer. 
Thymidine labelling 
Amadori et al.67 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Amadori et al.68 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Tanigawa et al.69 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To investigate the prognostic value of the tritiated 
thymidine LI 
28 
Prospective 
1-59 months (median 34 months) 
3-year survival significantly higher in patients 
with slowly proliferating tumors 
To investigate the prognostic value of c-myc, c-
K-ras, hst, c-erb B-2 gene amplification and of 
thymidine LI in gastric cancer. 
124 for gene amplification; 70 for thymidine 
labelling 
Prospective 
1-100 months (median 61 months) 
No correlation between thymidine LI and survival 
To investigate the prognosticvalue of the tritiated 
thymidine LI 
173 
Prospective 
Not available 
Thymidine LI is independent prognostic variable 
DNA flow cytometry 
Tosi et al.70 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate DNA ploidy pattern and behavior of 
the tumor 
133 
Retrospective 
6 years 
Significant correlation between DNA ploidy and 
survival 
74 
Significance of cell proliferation measurement in gastric cancer 
Table 3 (continued) 
Danova et al.71 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Ballantyne et al.72 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate DNA ploidy pattern and S-phase 
fraction with behavior of the tumor 
42 
Retrospective 
1 year 
Significant correlation between DNA ploidy and 
survival; No significant correlation between S-
phase fraction and survival 
To correlate DNA ploidy pattern and behavior of 
the tumor 
77 
Retrospective 
3 years 
No signifcant correlation between DNA ploidy 
and survival 
Sasaki et al.73 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate DNA ploidy pattern and behavior of 
the tumor 
70 
Prospective 
4 years 
No significant correlation between DNA ploidy 
and survival 
Ohyama et al.74 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To investigate the prognosticvalue of DNA ploidy 
pattern and BrdU LI 
117 
Prospective 
Not available 
DNA ploidy and BrdU LI independent prognostic 
parameters 
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Table 3 (continued) 
Yonemura et al.75 
Aim of the study To correlate DNA ploidy pattern and BrdU LI with 
behavior of the tumor 
No. of évaluable patients 493 
Type of study Retrospective 
Follow-up time Not available 
Results Significant correlation between DNA ploidy and 
survival 
Ohyama et al.76 
Aim of the study To correlate proliferation rate with behaviorof the 
tumor 
No. of évaluable patients 172 
Type of study Prospective 
Follow-up time 4 years 
Results Significant correlation between proliferative 
activity (BrdU LI/ DNA index) and survival 
Bromodeoxyuridine/lododeoxyuridine 
Ohyama et al.74 
Aim of the study To investigate the prognostic value of DNA ploidy 
pattern and BrdU LI 
No. of évaluable patients 117 
Type of study Prospective 
Follow-up time Not available 
Results DNA ploidy and BrdU LI independent prognostic 
parameters 
Yonemura et al.75 
Aim of the study To correlate DNA ploidy pattern and BrdU LI with 
behavior of the tumor 
No. of évaluable patients 493 
Type of study Retrospective 
Follow-up time Not available 
Results Significant correlation between DNA ploidy and 
survival 
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Table 3 (continued) 
Ohyama et al.76 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Yonemura et al.77 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate proliferation rate with behaviorof the 
tumor 
172 
Prospective 
4 years 
Significant correlation between proliferative 
activity (BrdU LI/ DNA index) and survival 
To study the prognostic significance of BrdU LI 
98 
Prospective 
4 years 
BrdU LI is independent prognostic factor 
PCNA 
Yonemura et al.33 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Yonemura et al.35 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate PCNA LI with behavior of the tumor 
121 
Retrospective 
5 years 
PCNA LI is independent prognostic factor 
To correlate PCNA LI with DNA ploidy and with 
behavior of the tumor 
174 
Retrospective 
5 years 
PCNA LI and DNA ploidy were independent 
prognostic factors 
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Table 3 (continued) 
Jain et al.37 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
Kakeji et al.64 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate PCNA LI with survival 
91 
Retrospective 
68 (73%) of the patients had been followed up for 
a minimum of 5 years 
PCNA LI was no independent prognostic factor; 
Semiquantitative PCNA grading was of 
independent prognostic value 
To correlate PCNA LI and AgNOR count with 
survival 
181 
Retrospective 
Not available 
PCNA LI was independent prognostic factor; 
AgNOR count was no independent prognostic 
facor 
Mori et al.78 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate PCNA LI with survival 
138 
Retrospective 
5 years 
PCNA LI was independent prognostic factor 
MIB-1 
Mueller et al.79 
Aim of the study 
No. of évaluable patients 
Type of study 
Follow-up time 
Results 
To correlate MIB-1 LI with survival 
418 
Retrospective 
5 years 
No significant correlation between MIB-1 LI and 
survival 
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Table 3 (continued) 
AgNOR 
Kakeji et al.64 
Aim of the study To correlate PCNA LI and AgNOR count with 
survival 
No. of évaluable patients 181 
Type of study Retrospective 
Follow-up time Not available 
Results PCNA LI was independent prognostic factor; 
AgNOR count was no independent prognostic 
facor 
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Summary 
Glutathione S-transferases (GSTs) are a family of isoenzymes that play an 
important role in protecting cells against cytotoxic and carcinogenic agents. 
The distribution and levels of GST Alpha and Pi in normal and malignant gastric 
tissue of 34 patients with gastric cancer were examined immunohistochemically. 
Expression of GST Alpha and Pi was observed in 47 and 100 percent of the 
tumors, respectively. Innormal mucosa both enzyme classes werepresent in 100 
percent of the specimens. Mucous cells showed staining for GST Alpha and Pi 
in 88 and 97 percent, parietal cells in 93 and 67 percent, and chief cells in 82 and 
30 percent, respectively. No correlation was observed between the amount or 
pattern of GST Alpha or Pi in carcinomas and the clinical and pathological 
characteristics of the patients. So it can be concluded that both GST Alpha and 
Pi cannot be considered as prognostic factors for gastric cancer. 
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Introduction 
The incidenceand mortality associated with gastricadenocarcinoma has decreased 
in manycountries during the past five decades1. However, despite newdiagnostic 
and therapeutic techniques, the 5-year survival rate of patients with advanced 
stage of gastric adenocarcinoma continues to be poor2. 
Two main histological types of gastric carcinoma were characterized by Lauren3, 
the intestinal type, resembling small bowel mucosa; and the diffuse type, 
infiltrating the stomach wall. The diffuse cancer has a poorer prognosis and is 
more common in women and younger patients". Biotransformation enzymes, and 
in particular glutathione S-transferases (GSTs) are present in most epithelial 
tissues of the human gastrointestinal tract5-8. Their presumptive function is to 
protect tissues against toxic or carcinogenic compounds, entering the body as 
food components, food additives or drugs59. Four classes of cytosolic GST 
isoenzymes exist in man: Alpha, Mu, Pi and Theta10·11. Expression of class Alpha 
and Pi enzymes is different in the various tissues. For instance, class Alpha 
enzymes are present in high levels in the liver1213, stomach14 and small intestine15, 
while class Pi enzymes are expressed in many organs, other than the adult 
liver1617. Increased expression of class Pi enzymes has been reported in a wide 
variety of human tumors, compared to the normal surrounding tissue1721. 
Interestingly, GST Pi expression in patients with node negative breast cancer22 
has been reported as a prognostic factor recently. To better understand the role 
of GSTs in gastric cancer and to study whether they have a predictive value, 
immunohistochemical expression of GST class Alpha and Pi was studied in 
gastric carcinoma and adjacent normal mucosa, in relation to patient and tumor 
characteristics, such as tumor type, stage, and the length of survival. 
Patients and methods 
Patients and tumor samples 
Tumor specimens and normal gastric tissue from 34 patients, who underwent 
primary surgery for gastric cancer between 1985 and 1989, were included in this 
study. Patient data are summarized in Table 1. Tumor stage was classified 
according to the criteria of the American Joint Committee on Cancer23. 
Selection for this study was based on the following criteria: formalin-fixed, 
paraffin-embedded specimens with both assessable tumor and normal mucosa 
must be available, patients must have undergone primary surgery, and clinical 
information of status at presentation and follow-up must be available. The study 
was approved by the local ethical committee on human experimentation. 
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Table 1 
Patient characteristics (η = 34). 
Age (years) 
Median 
Range 
Sex 
Male 
Female 
Tumor Stage 
Stage I 
Stage II 
Stage III 
Stage IV 
Tumor differentiation 
Undifferentiated 
Poorly differentiated 
Moderately differentiated 
Well differentiated 
Lauren Classification 
Diffuse 
Intestinal 
Indeterminate 
Survival (months) 
Median 
Range 
Immunohistochemical staining 
From each specimen three 4 pm thick slices were used: one for standard 
haematein eosin staining and two for immunohistochemical investigation of GST 
class Alpha and Pi. For immunohistochemical assays, sections of formalin-fixed 
paraffin-embedded tissue were dewaxed in xylol, rehydrated in ethanol and 
immersed in methanol with 2% hydrogen peroxide for 10 minutes to block 
endogenous peroxidase activity. Subsequently the sections were preincubated 
with phosphate-buffered-saline (PBS) containing 4% bovine serum albumin 
(BSA; Boehringer, Mannheim, Germany)and 0.1 % Triton X-100 (BDH Chemicals 
66 
43-76 
18 
16 
7 
9 
11 
7 
3 
19 
10 
2 
13 
17 
4 
20 
0->104 
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Figure 1 Immunostaining of GST Alpha and Pi in gastric adenocarcinoma and 
gastric mucosa. Space bar = 1081 pm. A. Tumor cells (T), heterogeneously 
positive for GST Alpha in gastric carcinoma. B. Normal gastric tissue showing 
strong positivity forGST Alpha in mucous cells (M) and parietalcells (P), while chief 
cells (C) were moderately positive. С Intestinal metaplasia showing strong 
immunoreactivity for GST Alpha. D. Diffuse staining for GST Pi in tumorcells (T). 
E. GST Pi expression in normal gastric tissue, showing intense positivity in 
mucous cells (M). F. GST Pi expression in intestinal metaplasia. 
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Ltd., Poole, England) to block nonspecific binding. The slides were incubated 
overnight at 4°C with primary antibodies against GST class Alpha (monoclonal 
antibody), as developed by us recently (Peters era/, 1992), diluted 1:5000 in PBS 
containing 4% BSA and 0.1 % Triton X-100 (buffer A) and GST class Pi (polyclonal 
antibody, Biotrin International, Dublin, Ireland) diluted 1:2400 in buffer A. 
Subsequently a45 minute incubation period at room temperature with peroxidase 
conjugated rabbit-anti-mouse immunoglobulin (Dakopatts, Glostrup, Denmark) 
diluted 1:100 in buffer A orperoxidase conjugated swine-anti-rabbit immunoglobulin 
(Dakopatts) diluted 1:40 in buffer A was performed for GST Alpha or Pi 
immunodetection, respectively. In order to enhance the intensity of the final 
staining a third incubation step was used: peroxidase conjugated swine-anti-
rabbit immunoglobulin (Dakopatts) diluted 1:40 in buffer A for GST class Alpha 
and peroxidase conjugated rabbit-anti-mouse immunoglobulin (Dakopatts) diluted 
1:100 in buffer A for GST class Pi. Staining was performed using 0.1% 3,3-
diaminobenzidine (Sigma Chemical Company, St. Louis, MO, USA) in PBS 
containing 0.01% hydrogen peroxide as peroxidase substrate. The slides were 
counterstained with haematein. Between each step the sections were wassed 
three times each for 5 minutes in PBS. Human livertissue and human colon tissue 
were used as a positive control for GST Alpha and Pi, respectively. Omission of 
primary antibodies served as negative controls. 
Scoring 
Both the intensity of staining and the proportion of stained cells were scored by 
three independent individuals. The intensity of staining was graded as follows: 
(-) negative, (+) weakly positive, (++) moderately positive, (+++) strongly positive. 
The proportion of cells showing staining was scored as follows: (0) <1 percent 
stained cells, (1)1-5 percent stained cells, (2) 6-25 percent stained cells, (3) 26-
50 percent stained cells, (4) 51-75 percent stained cells, (5) >75 percent stained 
cells. The distribution of staining was assessed by scoring tumor cells, mucous 
cells, parietal cells and chief cells, separately. 
Statistics 
Correlation between parameters was evaluated using the Spearman rank 
correlation test. In order to evaluate the differences in expression of the various 
cell types Friedman two-way Anova was used. In case of significant results (p < 
0.05) it was followed by the sign test. Kaplan Meier survival functions were 
constructed, and the relation between survival and expression of GST Alpha and 
Pi was analyzed using the generalized Wilcoxon test. Localization of the tumor, 
age, tumor differentiation grade and Lauren classification were included as 
covariates in the analysis. 
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Results 
GST Alpha 
The results of scoring the proportion of cells, staining for GST Alpha are 
summarized in Table 2 while intensity of staining is reported in Table 3. GST Alpha 
was present in 16 carcinomas (47 percent). Staining was generally focal and 
cytoplasmatic with staining of more than half the tumor cells in only 8 cases (Fig. 
1a). The adjacent normal mucosa showed positive immunoreactivity in all cases 
(Fig. 1b). Mucous cells were present in 33 specimens. Positive immunostaining 
of mucous cells was seen in 29 specimens (88 percent). In 20 sections (61 
percent) more than half of the mucous cells gave positive staining. Staining was 
predominantly cytoplasmatic and localized both in surface epithelium and in cells 
localized deeper within the crypts. In areas with intestinal metaplasia all affected 
cells showed very strong immunoreactivity (Fig. 1c). Parietal cells were seen in 
the normal mucosa of 28 cases. In 26 cases (93 percent) they showed diffuse 
cytoplasmatic and nuclear positivity for GST Alpha. Strongly positive 
immunoreactivity with dark staining of more than half the parietal cells was present 
in 21 cases (75 percent). Chief cells were present in 28 sections and positive 
staining was observed in 23 sections (82 percent), with a generally weak to 
moderate strong cytoplasmatic staining pattern. Staining of more than 50 percent 
of the chief cells could be observed in only 7 cases (25 percent). 
Intensity of stainingforGST Alpha and proportion of cells stained was significantly 
higher in parietal cells and in mucous cells than in chief cells and tumor cells (p 
<0.05). Connective tissue components (i.e. collagen, muscle etc.) were consistently 
negative. 
GST Pi 
Results of scoring the proportion of cells, staining for GST Pi are summarized in 
Table 2, while intensity of staining is given in Table 3. 
In all cases carcinoma showed positivity for GST Pi. Staining was predominantly 
cytoplasmatic, with additional nuclear staining in some cells (Fig. 1d). Staining 
intensity for GST Pi showed heterogeneity, showing tumor cells either negative, 
or positive with moderate to high intensity within the same tumor. In 28 cases (82 
percent) more than half of tumor cells were positive. Normal mucosa showed 
positive immunoreactivity in all cases. Mucous cells were positive in all sections 
in which they were present. In 32 cases (97 percent) more than half of the mucous 
cells were positive. The surface epithelium was strongly positive, while mucous 
cells located deeper within the crypts showed less intense staining (Fig. 1e). In 
sections with intestinal metaplasia all affected cells showed immunoreactivity 
(Fig. 1f). Parietal cells stained positive in 18 of the 27 sections in which they were 
present (67 percent). Staining was generally weak to moderate, with more than 
95 
Chapter 5 
Table 2 
Proportion of cells showing staining for GST Alpha and Pi in normal and 
neoplastic gastric tissue. 
Category* 
GST Alpha 
Tumor cells 
Mucous cells 
Parietal cells 
Chief cells 
GST Pi 
Tumor cells 
Mucous cells 
Parietal cells 
Chief cells 
0 
18 
4 
2 
5 
0 
0 
9 
19 
1 
1 
1 
0 
3 
0 
0 
7 
4 
2 
4 
1 
4 
9 
3 
0 
4 
1 
3 
3 
7 
1 
4 
3 
1 
5 
2 
4 
1 
3 
4 
4 
5 
2 
2 
1 
5 
7 
17 
17 
3 
23 
30 
0 
0 
Total 
34 
33 
28 
28 
34 
33 
27 
27 
* Categories explained in Patients and methods. 
The numbers indicate the number of cases falling into each category. 
Table 3 
Staining intensity of GST Alpha and Pi in normal and neoplastic gastric tissue. 
Category* ++ +++ Total 
GST Alpha 
Tumor cells 
Mucous cells 
Parietal cells 
Chief cells 
GST Pi 
Tumor cells 
Mucous cells 
Parietal cells 
Chief cells 
18 
4 
2 
5 
0 
0 
9 
19 
2 
3 
1 
12 
3 
1 
11 
6 
9 
9 
2 
10 
11 
12 
4 
2 
5 
17 
23 
1 
20 
20 
3 
0 
34 
33 
28 
28 
34 
33 
27 
27 
* Categories explained in Patients and methods. 
The numbers indicate the number of cases falling into each category. 
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Table 4 
Association of GST Alpha expression with clinical and pathological characteristics 
in 34 patients with gastric cancer. 
Proportion 
Category* 
Stage 
1 
II 
III 
IV 
Differentiation 
undifferentiated 
poorly differentiated 
moderately differentiated 
well differentiated 
Lauren classification 
diffuse 
intestinal 
indeterminate 
Survival, months 
<13 
13-24 
25-36 
>36 
of tumor cells showing expression of GST Alpha 
0 1 2 3 4 5 Total 
2 
7 
6 
3 
2 
10 
5 
1 
7 
7 
4 
7 
3 
1 
7 
1 
0 
0 
0 
0 
0 
0 
1 
0 
1 
0 
0 
0 
0 
1 
1 
0 
3 
0 
0 
2 
2 
0 
1 
3 
0 
2 
1 
0 
1 
1 
1 
1 
0 
0 
1 
2 
0 
1 
2 
0 
0 
1 
0 
2 
1 
0 
0 
0 
0 
0 
1 
0 
0 
1 
0 
1 
0 
0 
0 
1 
1 
1 
4 
1 
6 
0 
0 
4 
3 
0 
1 
3 
0 
3 
7 
9 
11 
7 
3 
19 
10 
2 
13 
17 
4 
11 
8 
1 
14 
* Categories explained in Patients and methods. 
The numbers indicate the number of cases falling into each category. 
50 percent positive in only 2 cases. Chief cells gave a weak immunoreactivity in 
only 8 of the 27 sections (30 percent) in which they were present. Intensity of 
staining for GST Pi and the proportion of cells stained was significantly higher in 
mucous cells and in tumor cells than in chief cells and in parietal cells (p < 0.05). 
Connective tissue components (i.e. collagen, muscle etc.) were consistently 
weakly positive. Plasma cells and lymphocytes showed strong nuclear and 
cytoplasmatic positivity. 
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Table 5 
Association of GST Pi expression with clinical and pathological characteristics 
in 34 patients with gastric cancer. 
Proportion of tumor cells showing expression of GST Pi 
Category* 0 1 2 3 4 5 Total 
Stage 
I 
II 
III 
IV 
Differentiation 
undifferentiated 
poorly differentiated 
moderately differentiated 
well differentiated 
Lauren classification 
diffuse 
intestinal 
indeterminate 
Survival, months 
<13 
13-24 
25-36 
>36 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
0 
2 
0 
0 
2 
1 
0 
2 
1 
0 
2 
0 
0 
1 
0 
2 
0 
1 
1 
1 
0 
1 
2 
1 
0 
1 
1 
0 
1 
1 
3 
0 
1 
0 
3 
1 
1 
1 
3 
1 
0 
3 
0 
2 
5 
4 
9 
5 
2 
13 
8 
0 
8 
12 
3 
g 
3 
1 
10 
7 
9 
11 
7 
3 
19 
10 
2 
13 
17 
4 
12 
7 
1 
14 
* Categories explained in Patients and methods. 
The numbers indicate the number of cases falling into each category. 
Correlation between GST Alpha or Pi expression with clinical and pathological 
findings 
In Table 4 and 5 the clinical and pathological characteristics of the tumors are 
compared with the proportion of tumor cells with detectable staining for GST 
Alpha and Pi, respectively. There was no significant correlation between expression 
of GST Alpha or Pi and clinical stage, tumordifferentiation and Lauren classification 
of the tumor (all ρ < 0.2). In addition, expression of GST Alpha or Pi in the tumor 
was not related with length of survival. 
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Discussion 
Gastric tumors are known to contain GST activity and previous studies have 
indicated that most of them express GST Pi and to a lesser extent GST Alpha'417 
However these studies were done on tissue homogenates which inevitably 
contain non-neoplastic elements such as stroma and which may even contain 
normal mucosa lmmunohistochemical analysis of GST Pi in gastric carcinoma 
was performed by Tsutsumi er a/2" They described high levels of GST Pi in all 
except for signet nng cell carcinomas In our study GST Pi was detected in 100 
percent of gastnc tumors, whereas GST Alpha was found in only 47 percent In 
many tumors there was a high expression of GST Pi in the accompanying stromal 
cells and inflammatory infiltrate Such observations emphasize the usefulness of 
lmmunohistochemical techniques in demonstrating the distribution of enzymes 
and other proteins in tissues and tumors, composed of a variety of different cell 
types 
Knowledge of the distnbution of GST tissue may improve our understanding of 
their function For example.what is the reason for the high expression of GST 
Alpha found especially in parietal cells, and of GST Pi in mucous cells of the 
surface epithelium? Furthermore, the biological significance of the heterogeneity 
in distribution of GST isoenzymes in gastnc cancer is unclear Intra-tumor 
variation of GSTs was also descnbed in lmmunohistochemical studies on human 
carcinomas of the cervix25, esophagus8, breast22 and kidney26 This vanation 
causes a complicating feature in the interpretation of GST expression Until now 
there was no evidence concerning the heterogeneity of GST in gastnc tumors 
Since GST activity may be relevant for detoxification of antineoplastic drugs18 the 
variability of GST expression suggests that different parts of the same tumors may 
have varying response to chemotherapy In addition, glutathione the cofactorfor 
GSTs9, is known to have a 2-3 fold vanation in concentration within a single 
tumor27 
lmmunohistochemical techniques also provide information on intracellular 
localization Antibodies against GST Alpha and Pi gave both cytoplasmatic and 
nuclear staining, which has also been descnbed in lmmunohistochemical studies 
of GSTs in the esophagus8, cervix28 and breast29 The significance and function 
of the nuclear localization is unclear and remains to be clanfied 
In contrast to the results of Gilbert et a/22 for breast cancer patients, in patients 
with gastnc carcinoma no apparent correlation of GST Alpha orPi expression with 
clinicopathological features or survival could be detected The high levels of GST 
Pi in all normal mucosa specimens investigated suggests that GST Pi expression 
is not directly related to malignancy in gastnc cancer However it should be noted 
that the normal gastnc mucosa used in this study was obtained from patients with 
gastnc carcinoma Although these tissues were microscopically normal, it is 
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possible that (part of) the tissue already has undergone changes in GST Pi 
expression. Therefore the examination of normal gastric tissue from patients 
without gastric diseases would help to resolve this question. Further investigations 
are nowbeen carried out to clarify thesignificanceandfunctionoftheheterogeneous 
GST expression in normal gastric tissue and in gastric carcinoma, especially in 
relation to anti-cancer drug resistance. 
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Summary 
Glutathione S-transferases (GSTs) are enzymes involved in the detoxification of 
xenobiotics and are divided into four subclasses, Alpha, Mu, Pi and Theta. Most 
human gastrointestinal tumors contain increased amounts of GST Pi. 
In order to compare data on the expression of GSTs obtained by biochemical as 
well as immunohistochemical methods, we characterized the presence of GST 
Alpha and Pi by Western blot analysis and immunohistochemistry in 22 samples 
of human gastric carcinoma and adjacent non-neoplastic mucosa. Biochemical 
analyses revealed the presence of GST Alpha and Pi in 95% and 91 % of normal 
tissues and in 82% and 100% of tumor specimens, respectively. 
Immunohistochemically all cases of normal gastric tissue stained for both GST 
Alpha and Pi, whereas immunostaining for GST Alpha and Pi was seen in 36% 
and 100% of thegastrictumorspecimens, respectively. No statistically significant 
correlation was observed between biochemical and immunohistochemical 
determination of GST Alpha and Pi both in normal as well as in malignant tissue. 
The absence of a statistically significant correlation between biochemical and 
immunohistochemical determination of GST Alpha and Pi implies that a high 
degree of caution must be taken in interpretating data derived solely from 
biochemical or immunohistochemical assays. 
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Introduction 
The glutathione S-transferases (GSTs) are a family of isoenzymes which catalyze 
the conjugation of glutathione (GSH) to a variety of electrophilic compounds 
which include carcinogens and cytotoxic drugs. Four classes of cytosolic GST 
isoenzymes with different biochemical and biophysical properties exist in man12: 
These are encoded at different gene loci and are classified as Alpha, Mu, Pi and 
Theta. These isoenzymes, most probably form part of an inherent protective 
mechanism against the development of tumors, by detoxifying chemical 
carcinogens present in the environment. However, there is increasing evidence 
for a role of GSTs in both acquired and intrinsic drug resistance in cancer 
chemotherapy2·3. Many anticancer drugs are considered to be detoxified by 
GSTs12. In addition, cells resistant to anticancer drugs overexpress GST 
proteins"6. The above data may imply that the levels of GST in the tumor could 
be a factor in determining the sensitivity of human tumors to cytotoxic drugs. 
Formercharacterization of GST expression in both normal and neoplastic human 
gastric tissue was done by an enzymatic assay using 1-chloro-2,4-dinitrobenzene 
(CDNB) and Western blot analyses78. These biochemical studies have shown 
that GST Pi is overexpressed in gastric tumors when compared to normal tissue, 
whereas GST Alpha content is higher in the normal epithelium. However, an 
important fact in considering such data is how cellular heterogeneity affects the 
overall isoenzyme expression. Immunohistochemical analysis is the technique 
used to address this issue. In this respect, we characterized the presence of GSTs 
in samples of human primary gastric carcinoma and adjacent non-neoplastic 
mucosa by biochemical methods and immunohistochemistry. 
Patients and methods 
Patients and tumor samples 
Specimens of normal gastric tissue and corresponding gastric adenocarcinoma 
from 22 patients, who underwent primary surgery for gastric cancer, were 
included in this study. Patient data are summarized in Table 1. Tumor stage was 
classified according to the criteria of the American Joint Committee on Cancer9. 
Gastrectomy specimens were obtained from the operating theatre. Samples to 
be used for biochemical analysis were excised immediately. Specimens of 
mucosa were taken from areas at least 5 cm away from the tumor and carefully 
stripped from the underlying muscle. Tumortissue was excised from non-necrotic 
areas. Tissue specimens were washed in cold phosphate-buffered-saline (PBS), 
quickly frozen in liquid nitrogen and stored at-80°C until required. Samples used 
forimmunohistochemical analysis were washed in cold PBS and fixed immediately 
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Table 1 
Patient characteristics (n = 22). 
Age (years) 
Median 68 
Range 35 - 85 
Sex 
Male 18 
Female 4 
Tumor Stage 
Stage IA 0 
Stage IB 4 
Stage II 3 
Stage INA 10 
Stage NIB 3 
Stage IV 2 
in 4% paraformaldehyde. The study was approved by the local Medical Ethical 
Review Committee. 
Preparation ofcytosolic fraction 
Tissue was homogenized in a glass/glass potter after dilution with approximately 
six volumes of 20 mM Tris/HCL buffer pH 7.4, containing 0.25M sucrose and 1.4 
mM dithiothreitol. After centrifugation at 150,000 g for 50 minutes the resulting 
supernatant was quickly frozen in liquid nitrogen and kept at -80°C until use. 
Biochemical assays 
The protein concentration was measured with bovine serum albumin as standard, 
and GST activity was determined using CDNB as substrate, as described 
before10. Class Alpha and Pi GSTswere quantified in the cytosolic fractions after 
densitometric analyses of immunoblots. Immunodetection was performed with 
monoclonal antibodies against class Alpha and Pi GSTs, as described before10. 
Immunohistochemical staining 
From each specimen three 4 μητι thick slices were used: one for standard 
haematein eosin staining and two for immunohistochemical investigation of GST 
class Alpha and Pi. Sections of formalin-fixed paraffin-embedded tissue were 
dewaxed in xylol, rehydrated in ethanol and immersed in methanol containing 2% 
hydrogen peroxide for 10 minutes to block endogenous peroxidase activity. 
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Subsequently the sections were preincubated with PBS containing 4% bovine 
serum albumin (BSA; Boehringer, Mannheim, Germany) and 0.1% Triton X-100 
(BDH Chemicals Ltd., Poole, England) to block nonspecific binding. The slides 
were incubated overnight at 4°C with primary antibodies against GST class Alpha 
(monoclonal antibody), as developed by us recently10, diluted 1:5000 in PBS 
containing 4% BSA and 0.1% Triton X-100 (buffer A) and GST class Pi (polyclonal 
antibody; Biotrin International, Dublin, Ireland) diluted 1:2400 in buffer A. 
Subsequently a 45 minute incubation period at room temperature with peroxidase 
conjugated rabbit-anti-mouse immunoglobulin (Dakopatts, Glostrup, Denmark) 
diluted 1:100 in buffer A orperoxidase conjugated swine-anti-rabbit immunoglobulin 
(Dakopatts) diluted 1:40 in buffer A was performed for GST Alpha or Pi 
immunodetection, respectively. In order to enhance the intensity of the final 
staining a third incubation step was used: peroxidase conjugated swine-anti-
rabbit immunoglobulin (Dakopatts) diluted 1:40 in buffer A for GST class Alpha 
and peroxidase conjugated rabbit-anti-mouse immunoglobulin (Dakopatts) diluted 
1:100 in buffer A for GST class Pi. Staining was performed using 0.1% 3,3-
diaminobenzidine (Sigma Chemical Company, St. Louis, MO, USA) in PBS 
containing 0.01% hydrogen peroxide as peroxidase substrate. The slides were 
counterstained with haematein. Between each step the sections were wassed 
three times each for 5 minutes in PBS. Human livertissue and human colon tissue 
were used as positive controls forGST Alpha and Pi immunostaining, respectively. 
In negative controls no primary antibodies were added. 
Both the intensity of staining and the proportion of stained cells were scored by 
three independent individuals. Staining intensity was graded as follows: 
(-) negative, (+) weakly positive, (++) moderately positive, (+++) strongly positive. 
The proportion of cells showing staining was scored as follows: (0) <1 percent 
stained cells, (1)1-5 percent stained cells, (2) 6-25 percent stained cells, (3) 26-
50 percent stained cells, (4) 51-75 percent stained cells, (5) >75 percent stained 
cells. The distribution of staining was assessed by scoring tumor cells and normal 
mucosa cells separately. 
Statistics 
Associations between biochemical and immunohistochemical analyses of GSTs 
were studied with Spearman rank correlations. 
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Results 
Biochemical determination of GST enzyme activity and GST Alpha and Pi levels 
Cytosolic levels of GST Alpha and Pi were determined after immunodetection 
with monoclonal antibodies on Western blots. GST Alpha and Pi were detectable 
in 21 (95%) and 20 (91 %) out of 22 normal tissues and in 18 (82%) and 22 (100%) 
of the 22 tumor samples examined, respectively. Mean levels of GST Alpha were 
lower in the tumors, whereas GST Pi content was higher in the gastric tumors, as 
compared to the corresponding normal mucosa (Table 2). 
Table 2 
Summary of biochemical analysis of GST Alpha and Pi content and of GST 
activity in normal and malignant gastric tissue. 
Normal stomach Adenocarcinoma 
(n=22) (n=22) 
GST Alpha content 
mean level* ± s.d. 1.99 ± 1.28 0.81 ± 1.27 
range 0 - 5.09 0 - 5.35 
GST Pi content 
mean level* ± s.d. 2.06 ± 2.24 3.31 ± 2.39 
range 0 - 3.62 0.08 - 8.68 
GST activity 
mean level" ± s.d. 317 ±170 405 ±209 
range 54 - 760 40 - 854 
*μg mg-1 protein 
"nmol mg1 protein.min 
Immunohistochemical analysis of GST Alpha and Pi expression 
All 22 cases of normal gastric tissue showed immunoreactivity with GST Alpha 
and Pi, whereas positive immunostaining for GST Alpha and Pi was seen in 8 
(36%) and 22 (100%) gastric tumors, respectively. The results of scoring the 
staining intensity as well as the proportion of cells stained are summarized in 
Table 3. From these data it is apparent that both the proportion of cells staining 
for GST Alpha as well ass the staining intensity were lower in gastric tumors 
compared to normal gastric mucosa, whereas the proportion of cells positive for 
GST Pi and the staining intensity were higher in the tumors than in normal gastric 
tissue. 
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Table 3 
Summary of immunohistochemical data of GST class Alpha and Pi in normal 
gastric tissues and gastric carcinomas. 
Normal stomach 
GST Alpha: intensity of staining 
negative 
weakly positive 
moderately positive 
strongly positive 
GST Alpha: proportion of cells staining 
<1% 
1-5% 
6-25% 
26-50% 
51-75% 
76-100% 
GST Pi: intensity of staining 
negative 
weakly positive 
moderately positive 
strongly positive 
GST Pi: proportion of cells staining 
<1% 
1-5% 
6-25% 
26-50% 
51-75% 
76-100% 
(n=22) 
0 
0 
2 
20 
0 
0 
1 
2 
5 
14 
0 
0 
9 
13 
0 
0 
2 
9 
6 
5 
Adenocarcinoma 
(n=22) 
14 
0 
6 
2 
14 
3 
2 
0 
1 
2 
0 
0 
7 
15 
0 
0 
0 
1 
1 
20 
Association of biochemical with immunohistochemical determination ofGSTs 
The levels of GST class Alpha and Pi as determined biochemically were 
correlated with the immunohistochemical data on staining intensity and proportion 
of cells stained for GST Alpha and Pi. The results are shown in Table 4. Except 
for GST Alpha in normal gastric mucosa, no statistically significant correlations 
were observed between biochemical and immunohistochemical determination of 
GST Alpha and Pi. 
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Table 4 
Correlation between biochemical determination of GST class Alpha and Pi 
levels with immunohistochemical determination. 
(r = correlation coefficient, ρ = p-value, η = number of patients) 
Biochemistry Immunohistochemistry 
Staining intensity Proportion of cells stained 
GST Alpha GST Pi GST Alpha GST Pi 
Normal 
Gastric 
Mucosa 
r=0.52 
p=0.01 
n=22 
r=-0.06 
p=0.80 
n=22 
r=0.10 
p=0.66 
n=22 
r=0.13 
p=0.56 
n=22 
Gastric 
Carcinoma 
r=0.27 
p=0.22 
n=22 
r=-0.22 
p=0.31 
n=22 
r=0.29 
p=0.19 
n=22 
r=-0.04 
p=0.87 
n=22 
Discussion 
The concentration of various GST isoenzymes in normal and tumor tissues is 
important for a variety of reasons. The levels in normal tissue may be a 
contributing factor in the susceptibility of tissue to cytotoxic damage by chemical 
toxins, carcinogens or some anticancer drugs. In the epithelia of the human 
gastrointestinal tract an inverse relationship between GST enzyme activity and 
tumor incidence has been demonstrated8. High levels of GST very efficiently 
detoxify several chemical carcinogens and protect tissue against DNA damage12. 
By contrast, in tumors the concentration of GST may be a factor in determining 
the degree of resistance to chemotherapy, since high levels of GST may rapidly 
detoxify anticancer drugs, thereby preventing their cytotoxic action12. 
In an earlier study we performed biochemical analyses of GST activities and GST 
isoenzyme contents of normal mucosa and matched gastrictumors7. An increased 
expression of GST Pi, at the expense of class Alpha GSTs was shown in gastric 
tumors. In an immunohistochemical study a similar observation was made by us 
recently11. However, great variability in GST tissue distribution was seen. High 
expression of GST Alpha was present in parietal cells, whereas GST Pi was 
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expressed in particular in mucous cells, at the surface of the epithelium and in 
tumor cells. Furthermore, heterogeneity in distribution of GST isoenzymes was 
observed, showing tumor cells as either negative or positive, with moderate to 
high intensity within the same tumor. Intra-tumor variation of GSTs was also 
described in immunohistochemical studies on human carcinomas of the cervix12, 
esophagus13, breast1" and kidney15. One of the major concerns in biochemical 
studies on GST expression and GST activity in human tissues is the lack of 
knowledge on the heterogeneity of expression. Therefore we performed a direct 
comparison of biochemical and immunohistochemical data of GST expression 
in gastric tissues. Our study, except for GST Alpha in normal mucosa, shows no 
statistically significant correlation between biochemical and immunohistochemical 
determinations of GST Alpha and Pi in normal gastric mucosa and gastric 
carcinoma. However, the overall conclusion obtained by both methods is 
identical: lower levels of GST Alpha and higher levels of GST Pi are found in 
gastric tumors, as compared to specimens of normal gastric tissue. There are a 
number of possible explanations for this discrepancy. At first, the heterogeneity 
of GST expression within normal gastric tissue and corresponding gastric 
carcinoma, as mentioned above, may be an important factor. Secondly, normal 
gastric mucosa and malignant tissue used for biochemical analyses was taken 
from gastrectomy specimens and homogenized. Although these specimens 
were judged as normal or malignant by macroscopical inspection and by 
investigation of neighbouring tissue by a pathologist, they may not be strictly 
normal ormalignant since no histological control of that particular part of the tissue 
was possible. Thirdly, we noted that GST Pi was also present in lymphoid cells. 
Furthermore, a high expression of both GST Alpha and Pi was seen in gastric 
epithelium with intestinal metaplasia. This implies that caution is needed in the 
interpretation of data derived solely from biochemical assays performed on 
homogenized tissues as they may give falsely raised values due to a high content 
of lymphoid cells or to the presence of intestinal metaplasia. 
A factor to be considered in interpretation of results of immunohistochemical 
analyses, is the possibility of interobserver variation. Howeverinorderto diminish 
this variation, in the presentstudy alltissue specimens were examined and scored 
by three independent individuals. 
In conclusion, a discrepancy between immunohistochemical and biochemical 
data on GST Alpha and Pi expression in normal and malignant gastric tissue was 
observed. Therefore caution is needed when interpretating data derived solely 
from biochemical assays, especially in tissues containing many different celltypes. 
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Summary 
Glutathione S-transferases (GSTs) are enzymes involved in the detoxification of 
xenobiotics and are divided into four subclasses, Alpha, Mu, Pi.andTheta. Most 
human gastrointestinal tumors contain increased amounts of GST Pi and GST 
enzyme activity. The relationship between GST parameters and tumor and 
patient characteristics, including overall survival, were studied retrospectively in 
normal and malignant gastric tissue from 49 patients with primary gastric 
carcinoma. Twelve patients (24%) were alive at the end of the study with a mean 
follow-up time of 4.1 ± 0.4 years Levels of GST Alpha, Mu, Pi and GST enzyme 
activity were not related to tumor stage, localization and diameter of the tumor, 
number of eosinophils in the tumor, presence of intestinal metaplasia in normal 
gastric mucosa, or gender and age of the patient. Optimal dichotomization and 
uni-and multivariate analyses were done with the Cox proportional hazard model. 
None of the clinicopathological parameters were associated with survival, except 
the number of eosinophils in the tumor. In contrast, high levels of GST Pi in both 
normal mucosa (Hazard ratio 3.0, ρ = 0.02) and in gastric carcinoma (HR 2.2, 
ρ = 0.05) and the presence of GST Mu in normal (HR 0.4, ρ = 0.05) and malignant 
(HR 0.3, ρ = 0.009) gastric tissue were found to have a significant prognostic 
value, independent from the clinicopathological parameters, when added 
separately to a Cox model. In conclusion the levels of GST Mu and Pi in both 
normal or carcinomatous gastric tissue have an independent prognostic impact 
on overall survival. 
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Introduction 
GSTs are enzymes that catalyze the nucleophihc addition of glutathione to 
electrophihc centres of a wide variety of compounds, mostly resulting in the 
elimination of potentially toxic compounds12 GSTs are also involved in the 
metabolism of several types ofanti-cancerdrugs3and are overexpressed in many 
human refractory tumors" Based on structural, physicochemical, enzymatic, and 
immunological properties cytosolicGSTsaredivided intofourclasses Alpha, Mu, 
Pi and Thêta2 5 
GST Pi IS the predominant subclass detected in gastnc tissue, in both normal 
mucosa6 and carcinomas7, while GST Mu and GST Alpha are present at lower 
concentrations Primary gastnc tumors contain higher amounts of GST Pi and 
GST enzyme activity compared to normal mucosa while the amounts of GST 
Alpha and Mu appear to be down-regulated in the tumor7 Not only gastnc 
carcinomas but also tumors from colon, unnary bladder, utenne cervix and lung 
contain increased amounts of GST Pi when compared to the adjacent normal 
tissue48, suggesting that high levels of this GST subclass may offer some 
advantage to cancer cells Gilbert er a/9 described that high levels of GST Pi in 
the tumor may be an important predictor of early recurrence and death in node-
negative breast cancer patients In accordance with these results we recently 
reported that colorectal cancer patients with high GST Pi level and GST enzyme 
activity in the tumor have a bad prognosis10 In the present study we examined 
GST classes Alpha, Mu, and Pi and GST enzyme activity in primary gastnc 
carcinomas and adjacent normal mucosa and its relationship with tumor and 
patient charactenstics, including overall survival 
Patients and methods 
Charactenstics of patients and tumors 
From 49 patients who underwent resection for primary gastnc carcinoma at the 
department of Surgical Oncology, University Hospital Leiden, fresh tissue was 
obtained Samples of a representee part of the tumor and of macroscopically 
normal mucosa, taken 5 -10 cm from the tumor, were selected by a pathologist 
and excised Tissue specimens were washed in ice cold phosphate-buffered 
saline (PBS), and stored at -70°C Clinical data of the patients and histological 
data of the carcinomas were registered Macroscopic pathological features as 
localization and diameter of the tumor, the Borrmann classification and the TNM 
classification according to the U I С С 198711 were retneved from the pathology 
reports Microscopic histological data of all the carcinomas (WHO and Lauren 
classification12, differentiation grade, numberof inflammatory cells and eosinophils 
as well as intestinal metaplasia) were revised by the same pathologist 
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All patients received primary surgical therapy. They entered the study at the 
operation date and had a clinical follow-up of at least 2 years for local recurrence 
and/or metastasis. Patient time experience ended in the event of death or at the 
closing date of the study (follow-up range 0.5-81 months). None of the patients 
was treated with chemotherapy. The study was approved by the local medical 
ethical review committee. 
Quantification of GST enzyme activity and GST subclasses 
Cytosolic fractions were prepared as described before13. Protein concentrations 
were determined according to Lowry et a/.14. GST enzyme activity was assayed 
by the method of Habig et a/.15 using 1-chloro-2,4-dinitrobenzene as substrate. 
Tumor cytosols were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and subsequent Western blotting13. Western blots were incubated 
with monoclonal antibodies against GST Alpha, Mu and Pi and the specific 
binding of the monoclonal antibodies to theirantigens was detected as previously 
described13. Staining intensity was quantified by laser densitometry (Ultroscan 
XL, LKB, Bromma, Sweden) using purified GSTs as marker proteins. Detection 
limit of this method is approximately 40 ng/mg protein and within-assay and 
between-assay variation is 10-15%. Class Alpha antibodies react against GST 
A1-1, GST A1-2 and GST A2-213, class Mu antibodies recognize GST M1a-1a, 
GST M1a-1b and GST M1b-1b1617, and class Pi antibodies are directed against 
GSTP1-118. 
Statistical analyses 
Univariate and multivariate survival analyses were performed with the Cox's 
proportional hazard model19 using the EGRET statistical package (SERC Corp. 
Seattle, WA). All clinicopathological parameters studied were dichotomized. The 
cut-off points of age, diameter, and GST parameters were determined by 
increasing the value until the level of best discrimination was found using Cox's 
univariate survival analysis, i.e. optimal dichotomization. Multivariate survival 
analyses were performed by separately adding the GST variables to a model 
containing seven clinicopathological parameters (TNM classification, localization, 
diameter and number of eosinophils of the tumor, intestinal metaplasia in the 
normal mucosa, gender and age of the patient) in order to estimate their 
independent prognostic value in the overall survival. Overall survival curves were 
constructed by the method of Kaplan and Meier20. Differences in GST parameters 
between normal and malignant samples were evaluated using the paired Student 
t-test. All data are given as mean ± standard error of the mean. Statistical values 
of p<0.05 were considered significant. 
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Table 1 
Characteristics of the patients with gastric carcinoma. 
Patients 
Gender (f/m) 
Age (years) 
Follow-up (years) 
Total 
49 
12/37 
66.9 ±1.7 
Alive 
12 (24%) 
2/10 
66.0 ± 4.3 
4.1 ±0.4 
Dead 
37 (76%) 
10/27 
67.2 ±1.8 
1.1 ±0.2 
Mean ± SEM; f = female, m = male. 
Results 
The characteristics of the 49 patients, operated for primary gastric cancer are 
presented in Table 1. Twelve patients (24%) were alive at the end of the study 
with a meanfollow-up time of 4.1±0.4years. Most of the patients were male (76%) 
and there was no significant difference in age between survivors and non-
survivors. 
GST Alpha, Mu and Pi were detectable in 48 (98%), 20 (41 %) and 49 (100%) of 
the normaltissues and in 31 (63%), 18 (37%) and 49 (100%) of thetumorsamples, 
respectively. The mean GST activity and the mean amounts of GST Alpha, Mu 
and Pi in normal gastric tissue and carcinoma are shown in Table 2. GST Alpha 
and Mu were significantly lower in carcinomas when compared to normal gastric 
mucosa. In contrast, gastric carcinomas had slightly higher GST Pi contents than 
normal gastric mucosa, but difference did not reach significance. 
Of the nine clinicopathological parameters evaluated in the univariate Cox 
proportional hazard analysis, only the presence of many eosinophils in the tumor 
had a significant impact on overall survival (p = 0.02, Table 3). Patients with 
intestinal metaplasia in the normal gastric mucosa had a slightly better survival, 
but differences did not reach significance (p = 0.07). The other clinicopathological 
parameters, i.e. the Lauren classification, differentiation, TNM stage, localization 
and diameter of the tumor and gender and age of the patient showed no 
association with survival. 
After optimal dichotomization of GST parameters, uni- and multivariate analyses 
were performed in order to reveal a possible association between these 
parameters and overall survival (Table 4). Dichotomization of GST Alpha in 
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normal gastric mucosa and of GST activity in gastric carcinoma was not possible, 
since no cut-off level could be determined. Univariate analysis indicated that 
several parameters were associated with the overall survival, i.e. a high GST Pi 
content and high GST enzyme activity in normal mucosa (HR 3.0, ρ = 0.003, and 
HR 2.2, ρ = 0.04, respectively) and a high GST Alpha content in the tumor (HR 
2.0, ρ = 0.04) were significantly associated with a poor overall survival. 
When the GST parameters were added separately to a multivariate Cox analysis 
containing all the clinicopathological parameters (i.e. gender, age, TNM 
classification, localization, diameter, number of eosinophils in the tumor and the 
presence of intestinal metaplasia in the normal mucosa), several significant 
associations were found (Table 4 and Figure 1). The presence of GST Mu both 
in normal mucosa and in carcinoma was associated with good prognosis (HR 0.4, 
ρ = 0.05, and HR 0.3, ρ = 0.009, respectively), which was not found in the 
univariate analysis, whereas a high GST Pi level both in normal mucosa and 
tumor, was associated with a bad overall survival (HR 3.0, ρ = 0.02, and HR 2.2, 
ρ = 0.05, respectively) independent from the clinicopathological parameters. GST 
activity in normal mucosa (HR 1.5, ρ = 0.49) and GST Alpha level in the tumor (HR 
2.0, ρ = 0.06) lost their prognostic significance from the univariate analysis. 
Table 2 
Levels of glutathione S-transferases in normal and malignant tissue of 49 
patients with gastric cancer. 
Normal Carcinoma p-value 
GST-Alpha 
(pg/mg protein) 2.13 ±0.19 0.60 ±0.13 < 0.001 
GST-Mu 
(pg/mg protein) 0.38 ± 0.09 0.20 ± 0.05 < 0.003 
GST-Pi 
(pg/mg protein) 2.54 ±0.17 2.85 ±0.25 NS 
GST enzyme activity 
(nmol/min.mg protein) 334 ±22 305 ±23 NS 
Mean ± SEM, NS = not significant. 
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Table 3 
Univariate Cox analysis of clinicopathological parameters in relation to overall 
survival. 
Parameter dichotomized (n) No. survivors (%) Hazard ratio 
(95% CI, p-value) 
Gender 
Male (37) 
Female (12) 
Age (years) 
< 66.3 (24) 
> 66.3 (25) 
Lauren classification 
Diffuse/mixed (18) 
Intestinal (31) 
WHO classification 
Differentiated (34) 
Undifferentiated (15) 
TN M classification 
Stage l+ll (34) 
Stage lll+IV (15) 
Localization of the tumor 
Antrum (22) 
Other (27) 
Diameter of the tumor 
< 5 cm (27) 
> 5 cm (22) 
Eosinophils in the tumor 
Many (7) 
Few/moderate (42) 
Intestinal metaplasia in normal mucosa 
Absent (18) 
Present(31) 
10 
2 
5 
7 
6 
5 
5 
6 
10 
2 
7 
5 
7 
5 
0 
12 
2 
10 
(27) 
(17) 
(21) 
(28) 
(33) 
(16) 
(15) 
(40) 
(29) 
(13) 
(32) 
(19) 
(26) 
(23) 
(29) 
(11) 
(32) 
1.1(0.5-2.2, NS) 
1.2(0.6-2.3, NS) 
1.7(0.8-3.4, NS) 
0.6(0.3-1.2, NS) 
1.3(0.7-2.6, NS) 
1.6(0.8-3.2, NS) 
1.1 (0.6-2.1, NS) 
0.4(0.2-0.8, 0.02) 
0.5(0.3-1.1,0.07) 
CI = confidence interval, NS = not significant, η = number of patients 
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Table 4 
Uni- and multivariate analysis of glutathione S-transferase parameters in normal 
gastric mucosa and gastric carcinomas related to overall survival. 
Cox proportional hazard analysis 
(95% CI, Ρ value) 
Parameter dichotomized (n) No. Univariate hazard Adjusted hazard 
survivors(%) ratio ratio 
Normal gastric mucosa 
GST-Mu (мд/rng protein) 
Absent (29) 5 (17) 
Present (20) 7 (35) 0.8(0.4-1.6,0.51) 0.4(0.1-1.0,0.05) 
GST-Pi (мд/тд protein) 
< 3.20 (37) 12 (32) 
> 3.20 (12) 0 3.0(1.5-6.1,0.003) 3.0(1.2-7.8,0.02) 
GST enzyme actvity 
(nmol/min.mg protein) 
< 450 (39) 11 (28) 
> 450 (10) 1 (10) 2.2(1.0-4.8,0.04) 1.5(0.5-4.5,0.49) 
Gastric carcinoma 
GST-Alpha (pg/mg protein) 
< 0.30 (30) 9 (30) 
> 0.30 (19) 3 (16) 2.0(1.1-3.9,0.04) 2.0(1.0-4.1,0.06) 
GST-Mu (pg/mg protein) 
Absent (31) 5 (16) 
Present (18) 7 (39) 0.6(0.3-1.3,0.20) 0.3(0.1-0.8,0.009) 
GST-Pi (мд/тд protein) 
< 4.00 (38) 12 (32) 
> 4.00 (11) 0 1.9(0.9-4.0,0.07) 2.2(1.0-4.9,0.05) 
CI = Confidence interval, η = number of patiens 
Adjusted hazard ratios were calculated by adding the glutathione S-transferase 
parameters separately to a model containing the clinicopathological parameters 
gender, age,TNMclassification, localization, diameter, eosinophils, intestinal metaplasia 
in the normal mucosa. 
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Figure 1 
Overall survival curves of patients dichotomized according to (A) GST-Pi level 
(<3.20 vs. >3.20 Mg/mg protein) and (B) GST enzyme activity (< 450 vs. > 450 
nmol/min.mg protein) of the normal gastric mucosa and (C) GST-Alpha level 
(<0.30 vs. >0.30 pg/mg protein), and (D) GST-Pi level (<4.00 vs. >4.00 ng/mg 
protein) of the carcinomas. Values are the number of patients dead/alive at the 
end of the follow-up. For p-values and hazard ratios see Table 4. 
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Discussion 
The prognosis of gastric cancer is extremely poor with 5-year survival rates 
ranging from 5% to 15%21. This is related to the fact that in Western countries the 
majority of patients are diagnosed with advanced disease. Factors known to 
influence clinical outcome in gastric cancer include localization of the primary 
tumor, the presence or absence of lymph node involvement, and the depth of 
penetration of the gastric wall22 23. Curative resection remains the most effective 
treatment and includes removal of the primary tumor and regional lymph nodes 
with resection margins free of tumor. Unfortunately, only approximately 40% of 
patients are candidates for potentially curative resection and despite this 
intervention, the majority of patients will develop locoregional disease and 
eventually die of metastatic disease22 24. Efforts to increase the cure rate in gastric 
cancer have focused on systematic lymph node dissection in an effort to 
completely excise the tumor2527. Down staging of primary tumors with active 
preoperative chemotherapy is another approach to improve survival28 29. In this 
respect, it is of great importance to understand more about the biological behavior 
of gastric cancer Pathophysiological markers which allow the identification of 
subgroups of patients with good or poor prognosis might help to select patients 
for above mentioned therapies. In our study, the presence of many eosinophils 
in the tumor (survival 0%) was the only clinicopathological parameter with a 
significant predictive value for overall survival. The observation that a severe 
intratumoral inflammatory reaction, mostly lymphocyticand eosinophilic infiltration, 
is associated with survival has also been reported by Iwasaki et al.30. 
In the present study we analyzed the prognostic relevance of the GST system in 
primary gastric carcinomas and their normal tissues counterparts, in comparison 
with major clinicopathological parameters. The amounts of GST Alpha and Mu 
were significantly lower in gastric carcinomas compared to normal gastric tissue. 
Malignant tumors of the gastrointestinal tract, e.g. esophagus, stomach and 
colorectum, are often characterized by high levels of GST Pi4·7 8·13 3132, suggesting 
that these elevated levels may offer a selective advantage to the tumor cells. In 
our gastric cancer patient population we found that several GST parameters, 
determined in both normal mucosa and carcinomas, were associated with overall 
survival. Univariate analysis revealed that high levels of GST enzyme activity and 
GST Pi in the normal mucosa and high levels of GST Alpha in the tumor were 
significantly associated with a poor survival. When added separately to a 
multivariate Cox model, containing all clinicopathological parameters, the absence 
of GST Mu and high levels of GST Pi, both in normal gastric tissue and in gastric 
carcinoma, were significant prognostic parameters for poor overall survival. 
GSTs are involved in the metabolism of several types of anticancer drugs3. 
Increased GST concentrations, most notably GST Pi, have been implicated as 
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a resistance mechanism in cell lines selected for resistance toward various 
cytostatic drugs4. Although few studies relating GST expression to clinical 
outcome were performed in patients treated with anticancer drugs, there is some 
evidence for a relationship between GST Pi expression in carcinomas and 
survival. Two studies in patients with leukemia have shown that high GST enzyme 
activity33 and high GST Pi expression34 were correlated with a poor clinical 
response, and two studies in patients with ovarium tumors indicated that a low 
level of GST Pi was prognostic for response to chemotherapy and prolonged 
survival3536. In contrast, GST activity and isoenzyme distribution did not predict 
respons to chemotherapy in two other series of patients with ovarian cancer37 38 
and in a study of patients with leukemia39. In women with axillary node-positive 
breast cancer who had received adjuvant chemotherapy, expression of GST Pi 
was without predictive value4041. However, in a study from Gilbert et al.9, high 
expression of GST Pi was a strong predictor of relapse and death in the subgroup 
of women with axillary node-negative breast cancer, none of whom had received 
chemotherapy prior to relapse. Taken together these data show that a possible 
relationship between GST Pi expression and prognosis may exist, which is 
independent of any interaction between GST Pi and chemotherapy. GST Pi 
expression was correlated with survival in patients with colorectal tumors10 or 
renal cell carcinomas42, and with pathologically-defined biologically-aggressive 
features in human softtissue sarcomas43, again confirming that GST Pi expression 
may be a marker for a phenotype associated with poor clinical outcome. 
Increased GST Pi expression by itself could directly affect prognosis in gastric 
cancer, however it is also possible that this enzyme level is changed in parallel 
with more important markers that determine the clinical course of this disease. 
Therefore understanding of the regulation of expression of GST Pi may help 
identifying such possible factors. 
In a study by Okuyama era/.44 the relationship between GST Pi expression in the 
tumor and survival of patients with gastric cancer was investigated, but no 
association was found. However, staining results of gastric tumors for GST Pi in 
their study (56% positive) were rather different from our results (100% positive) 
or from that of the study of Tsutsumi et a/.45 where 91 % positivity was reported 
in non-signet ring cell gastric carcinomas. 
It is of particular interest that in our study, the absence of GST M1-1 in normal 
mucosa and in tumor tissue was correlated with a poor survival. In a normal 
population 40 - 50% of the subjects lack this isofomn16 ^ 47. The significance of this 
heterogeneity in expression is not clear, but there is some evidence that 
individuals with a genetic GST M1-1 deficiency have an increased risk of 
developing carcinomas, including those of the stomach46 47. Ourfindings suggest 
a worse prognosis for gastric cancer patients without GST M1-1 expression. 
In conclusion, GST Pi levels and the presence of GST M1-1 in normal gastric 
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tissue and in gastric carcinomas are independent prognostic variables for overall 
survival in patients with gastric cancer, and could be used in identifying subgroups 
of patients for additional (chemo)therapy. 
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Summary 
In vivo labelling with synthetic thymidine analogues, such as iododeoxyuridine 
(IdU) and bromodeoxyuridine (BrdU), has frequently been used to estimate tumor 
proliferation. However, this method requires intravenous administration of IdU or 
BrdU, thymidine analogues that are potential mutagens. Recently, the monoclonal 
antibody MIB-1 was developed, recognizing the Ki-67 nuclear antigen, which is 
associated with cell cycle proliferation and found throughout the cell cycle (G v S, 
G2 and M phases), but not in resting (G0) cells. We studied the correlation of the 
MIB-1 labelling index (LI) and the IdU LI in normal and malignant gastric tissue. 
Twenty patients with gastric cancer received an intravenous injection of IdU (200 
mg/m2) before surgery. Specimens were obtained from gastric carcinoma and 
adjacent normal gastric tissue. Samples were fixed in formalin and 
immunohistochemical analyses of IdU LI and MIB-1 LI were performed. The LI 
was defined as percentage of labelled nuclei of 5000 nuclei counted. 
The IdU LI ranged from 3.3% to 18.2% in gastriccarcinoma and from 0.5% to 5.6% 
in adjacent normal gastric mucosa, whereas the MIB-1 LI ranged from 4.2% to 
46.0% in gastric cancer and from 1.3% to 25.1% in adjacent normal gastric 
mucosa. Comparison of IdU LI with MIB-1 LI, using Spearman rank correlation 
coefficient test, showed a significant correlation between IdU LI and MIB-1 LI in 
normal gastric tissue (r=0.63, p<0.05). However, in gastriccarcinoma no significant 
correlation was found between both proliferation markers (r=0.07, N.S.). 
In conclusion, MIB-1 accurately reflects the "in vivo" IdU LI in normal gastrictissue. 
However, in gastric carcinoma the MIB-1 LI does not seem to be a substitute for 
the "in vivo" IdU LI. 
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Introduction 
Although the overall incidence of gastric cancer has steadily declined during the 
past 50 years in the Western world, it is still a major health problem and it remains 
the most common cancer in the world1. The prognosis of gastric cancer is 
particularly poor with an overall five year survival for subjects with resectable 
gastric cancerof20%2. Morphological criteria such as histological type, histological 
grade, and growth pattern have been studied as prognostic parameters for gastric 
cancer, but can not be used to predict clinical outcome3. 
Information on cell kinetics may be a useful adjunct to histologically based tumor 
classifications in the understanding of tumor behavior. In particular, during the last 
few years, several studies consistently identify the prognostic relevance of cell 
proliferative activity in gastric cancer414. 
Different approaches were used to evaluate the cell kinetics of human gastric 
cancer. Labelling studies with iododeoxyuridine (IdU) or bromodeoxyuridine 
(Brdll)15 have been performed to identify the growth potential of individual tumors. 
The IdU labelling index (LI), indicating the S-phase fraction, is a reliable measure 
of the growth potential and biological malignancy of gastric cancer4'61619. 
However, this method requires intravenous administration of IdU, a thymidine 
analog that is a potential mutagen20. In vitro labelling of surgical specimens is 
another option, which however has not been sufficiently studied to establish its 
routine applicability forwidespread use. Therefore other techniques were sought 
that might substitute for "in vivo" IdU or BrdU labelling. In order to study the 
proliferative activity of gastric cancer, the expression of several proliferation-
associated nuclear proteins, including proliferating cell nuclear antigen 
(PCNA)791012·13·2126 and Ki-67 antigen27 have been examined. Immunostaining of 
these proteins is affected by various factors that limit their widespread use. For 
instance, immunohistochemical determination of proliferation using PCNA may 
not accurately reflect the proportion of cells in the growth cycle28. The number of 
PCNA immunoreactive nuclei may be altered by different tissue processing 
techniques29 30, and the half-life of the PCNA antigen exceeds the cell cycle time31. 
Consequently, proliferation rates based on PCNA immunohistochemistry may be 
an inaccurate estimate ofthenumberof proliferating cells. Immunohistochemistry 
with the Ki-67 antibody is another potent method of determination of proliferation. 
The Ki-67 monoclonal antibody was developed by immunizing mice with a crude 
nuclear fraction of a cell line derived from a Hodgkin's lymphoma, and recognizes 
a nuclear antigen in proliferating cells32 33. A major obstacle to the routine use of 
antibody Ki-67 lies in the fact that it can be applied only on fresh or frozen tissue, 
because the epitope detected by Ki-67 is destroyed by tissue fixation34. Recently 
the monoclonal antibody MIB-1 has been developed using recombinant portions 
of the Ki-67 nuclear antigen as an immunogen. MIB-1 recognizes the Ki-67 
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nuclear antigen associated with cell proliferation and found throughout the cell 
cycle (Gv S, G2 and M phases), but not in resting (G^ cells3537. MIB-1 was shown 
to be a robust marker of cell proliferation37. On paraffin wax embedded tissue 
sections, using a microwave antigen retrieval method, the MIB-1 antibody gives 
an immunohistochemical staining pattern which is identical with that of the Ki-67 
antibody in frozen sections3436. As it is important to comparea new technique with 
a recognized standard, we compared the MIB-1 LI and the "in vivo" IdU LI in normal 
and malignant gastric tissue from 20 patients with gastric cancer. 
Patients and methods 
Patients and tumor samples 
Tumor specimens and normal gastric tissue from 20 patients, who underwent 
primary surgery for gastric cancer, were included in the study Patient data are 
summarized in Table 1. Tumor stage was classified according the criteria of the 
American Joint Committee on Cancer38. IdU was administered as a 15 minutes 
intravenous infusion, 200 mg/m2 (maximum dose 400 mg), 3-6 hours before 
resection of the tumor. No IdU related side-effects were seen during or after the 
administration. Permission to administer IdU was obtained from the local Medical 
Ethical Review Committee. Informed consent was obtained from each patient. 
Table 1 
Patient characteristics (n = 20). 
Sex 
Male 15 
Female 5 
Age (years) 
Median 64 
Range 46 - 85 
Tumor stage 
Stage I 5 
Stage II 8 
Stage III 7 
Stage IV 0 
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Tissue preparation 
Immediately after surgery, representative parts of tumor and normal surrounding 
gastric tissue were excised, cooled on ice and transported to the laboratory. Small 
tissue blocks (250 mm3) were fixed in formalin, and subsequently paraffin 
embedded according to routine procedures. From each specimen three 4 μητι 
thick slides were used: one for standard haematein eosin staining and two for 
immunohistochemical investigation of IdU and MIB-1. 
Idil immunohistochemistry 
Tissue sections were dewaxed in xylol, rehydrated in ethanol and immersed in 
methanol with 2% hydrogen peroxide for 10 minutes to block endogenous 
peroxidase activity. Subsequently, the sections were treated with 0.05 mg/ml 
pepsin (Boehringer, Mannheim, Germany) diluted in phosphate buffered saline 
(PBS) for 30 minutes at 37°C. The slides were then hydrolysed in 2 M HCl at 37° 
for 18 minutes and then neutralised in 0.1 M boric acid buffer (pH 8.5). 
Subsequently, the slides were incubated overnight at 4°C with primary antibody 
against IdU (a kind gift of the department of Pathology, University Hospital 
Nijmegen), diluted 1:40,000 in PBS containing 2% normal rabbit serum (NRS) 
and 2% bovine serum albumin (BSA) (Buffer A). Peroxidase labelled rabbit 
secondary antibody against mouse immunoglobulins (Dakopatts, Glostrup, 
Denmark) diluted 1:100 in buffer A was applied for 45 minutes at room 
temperature. Staining was performed using 0.1 % 3,3-diaminobenzidine (Sigma 
Chemical Company, St. Louis, MO, USA) in PBS containing 0.01% hydrogen 
peroxide. Ultimately the tissues were treated with 0.5% CuS04 for 5 minutes and 
counterstained with haematein. Between each step the sections were washed 
three times for 10 minutes in PBS. 
MIB-1 immunohistochemistry 
Tissue sections were first mounted on Superfrost Plus Slides (Menzel, Gläser, 
Germany) and air-dried overnight at 60°C. After dewaxing in xylene and 
rehydrating through graded alcohol, the sections were immersed in 2% hydrogen 
peroxide in methanol for 10 minutes to block endogenous peroxidase activity. 
Subsequently, the tissues were placed in citric acid buffer (10 mM, pH 6.0) and 
heated in a microwave forthree times 5 minutes (850 W). The slides were cooled 
to room temperature, and subsequently incubated for 1 hour with primary 
antibody to Ki-67 (MIB-1, Immunotech, Marseille, France), diluted 1:40 in PBS 
containing 2% NRS, 2% BSA and 0.1 % Triton X-100 (BDH Chemicals Ltd, Poole, 
England) (buffer B). Biotinylated rabbit secondary antibody against mouse 
immunoglobulins (Dakopatts, Glostrup, Denmark) diluted 1:400 in buffer В was 
applied for 45 minutes. Subsequently, the tissues were incubated with avidin-
biotin complex (ABC complex, Dakopatts, Glostrup, Denmark) for 45 minutes. 
The chromogen 0.1 % 3,3-diaminobenzidine in PBS containing 0.01 % hydrogen 
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peroxide, was applied for3 minutes. Ultimately the tissues were treated with 0.5% 
CuS04 for 5 minutes and counterstained with haematein. Between each step the 
sections were washed three times for 10 minutes in PBS. All antibody reactions 
were performed at room temperature. 
Evaluation of immunohistochemistry 
The slides were evaluated by 2 independent observers, using a standard light 
microscope with a X40 objective. At least 5000 epithelial cells of normal gastric 
tissue and 5000 tumor cells on each slide were counted to determine the 
percentage of IdU or MIB-1 positive cells, respectively. IdU or MIB-1 LI was 
defined as the percentage of labelled cells to total cells. 
Statistical analyses 
Associations between IdU LI and MIB-1 LI were studied with Speanmank rank 
correlation test. 
Results 
lododeoxyuridine labelling index 
In normal gastrictissue.ldU-positive cells were frequently observed inand around 
the mucosal neck zone of the glands. The IdU LI of the 20 specimens of normal 
mucosa ranged from 0.5 to 5.5%, with a mean of 2.6% (SD 1.5). In tumor tissue, 
IdU-positive cells were detected in all cases, although heterogeneity within the 
tumors and intertumoral variations were evident. The IdU LI of the tumors ranged 
widely from 3.3 to 18.2%, with a mean of 7.8% (SD 3.9). Neither in normal gastric 
tissue nor in gastric carcinoma, there was a correlation between the incubation 
period of IdU (time between administering of IdU and resection) and the IdU LI. 
As shown in Figure 1, IdU staining was entirely confined to the nuclei. 
MIB-1 labelling index 
Positivity for MIB-1 monoclonal antibody was confined to the cell nucleus (see 
Figure 1). The sections were homogeneously stained without background. Some 
gradation in the intensity of nuclear staining could be seen within the same 
section, but it was always easy to determine whether a nucleus was positive. As 
a consequence the interobserver variation in scoring was very low. 
The MIB-1 LI of the 20 specimens of normal mucosa ranged from 1.3 to 25.1 %, 
with a mean of 8.4% (SD 5.9). In tumortissue, MIB-1 LI ranged from4.2%to 46.0% 
(mean 25.5%, SD 11.9). 
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Figure 1 Immunostaining of IdU and MIB-1 in gastric mucosa and gastric 
carcinoma. Space bar= 1 μΜ. A. IdU immunostaining of gastric mucosa. B. IdU 
immunostaining of gastric carcinoma. С MIB-1 immunostaining of gastric 
mucosa. D. MIB-1 immunostaining of gastric carcinoma. E. Haematein eosin 
staining of gastric mucosa. F. Haematein eosin staining of gastric carcinoma. 
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Correlation of iododeoxyuridine labelling index and MIB-1 labelling index 
The proportion of MIB-1 positive cells was greater in most specimens than IdU 
positive cells. The distribution of IdU and MIB-1 LI is shown in Table 2. When this 
was analysed using the Spearman rank correlation coefficient test, a correlation 
coefficient of 0.63 (p<0.05) was found in normal gastric tissue, whereas in 
malignant gastric tissue there was no statistically significant correlation (r=0.07, 
N.S.). 
Table 2 
Distribution of IdU LI and MIB-1 LI in normal gastric tissue and gastric 
carcinoma. 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Normal gastric tissue 
IdU LI MIB-1 LI 
(%) (%) 
1.4 2.8 
5.6 5.3 
3.8 15.6 
1.1 4.5 
2.5 6.5 
1.3 3.7 
4.3 5.4 
0.5 2.4 
4.0 25.1 
2.2 15.6 
4.8 10.3 
1.2 1.3 
2.2 6.9 
1.1 4.0 
4.5 9.7 
1.3 5.5 
2.0 8.7 
2.9 11.7 
2.8 15.7 
2.6 7.2 
Gastric carcinoma 
IdU LI MIB-1 LI 
(%) (%) 
11.1 11.2 
12.3 12.2 
9.7 23.2 
18.2 37.9 
5.4 28.9 
5.0 4.2 
6.6 43.1 
3.7 9.5 
7.2 16.9 
3.9 17.5 
13.0 28.7 
13.1 29.2 
6.8 43.5 
7.0 46.0 
6.2 23.0 
3.3 30.3 
7.6 19.4 
8.1 20.8 
4.8 36.2 
3.9 27.6 
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Discussion 
The assessment of cellular proliferation may give important information on the 
malignant potency of a tumor. A variety of methods can be used to quantify this. 
Ideally such methods should be simple, reproducible, and applicable to routine 
processed histological preparations. The method should be relatively inexpensive 
and interpretation of the results should be straightforward. IdU is a thymidine 
analogue suited for "in vivo" pulse labelling studies. However, IdU shares a 
theoretical risk of mutagenicity. Although no evidence for acute or long term 
toxicity has emerged, its clinical research use should be restricted to consenting 
adults with malignant disease. As there is need for accurate measurement of cell 
proliferation which can be performed on routinely processed material, and which 
is neither time consuming nor labour intensive, the development of MIB-1 
antibody, recognizing the Ki-67 antigen, has been put forward35 36. To determine 
whether MIB-1 labelling can be used as an "in vitro" marker of cell proliferation in 
normal and malignant gastric tissue, we have compared it with "in vivo" IdU 
labelling. We found an "in vivo" mean IdU LI of 2.6% (range 0.5 - 5.6%) and 7.8% 
(range 3.3 -18.2%) in normal and malignant gastric tissue, respectively. These 
data are in general agreement with results about in vivo IdU or BrdU LI derived 
from literature (Table 3). In our study a mean MIB-1 LI of 8.4% (range 1.3- 25%) 
wasfound in normal mucosa. In tumortissue, MIB-1 LI ranged from 4.2% to 46 0% 
(mean 25.5%). Results of determination of MIB-1 LI as described in the literature 
are summarized in Table 4. These data are broadly comparable to our data, since 
other investigators also found wide variety in both normal gastric epithelium and 
gastric tumors 
Our results show a much greater expression of MIB-1 than of IdU in normal and 
neoplastic gastric epithelium. This can be explained by the presence of MIB-1 
antigen in all active parts of the cell cycle, whereas incorporation and subsequent 
detection of IdU is only possible in the S-phase fraction. 
We found a significant correlation between IdU LI and MIB-1 LI in normal gastric 
tissue, whereas in gastric carcinoma no significant correlation was found. Our 
results in normal gastrictissue are in excellentagreement with the results of Lynch 
et al.39, who compared MIB-1 and "in vitro" BrdU LI in endoscopic gastric biopsy 
specimens of normal mucosa. In their study the correlation coefficient for MIB-1 
and BrdU was 0.63 (p<0.001). We found a lack of correlation between "in vivo" 
IdU LI and MIB-1 LI in gastric carcinomas. This was not found in all malignant 
tumors investigated so far. A significant correlation between "in vivo" BrdU LI and 
MIB-1 LI was described in cerebral gliomas4041. The lack of correlation between 
IdU LI and MIB-1 LI in gastric carcinoma could be attributed to several factors. 
Primarily, it could be caused by heterogeneity of proliferation within the tumor. 
Furthermore, it could be due to a the variety in incubation periods of IdU (time 
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Table 3 
Immunohistochemical determination of IdU LI or BrdU LI: data from literature. 
Tissue 
Normal gastric mucosa 
Normal gastric tissue adjacent to carcinoma 
Normal gastric tissue far from carcinoma 
Antrum mucosa 
Antrum mucosa 
Antrum mucosa 
Antrum mucosa of patients with 
Helicobacter pylori negative gastritis 
Antrum mucosa of patients with 
Helicobacter pylori positive gastritis 
Antrum mucosa of patients with 
Helicobacter pylori positive gastritis 
Antrum mucosa of patients with 
atrophic gastritis 
Antrum mucosa of patients with early 
gastric cancer 
Antrum mucosa of patients with gastric cancer 
Antrum т и г л « я Ы natipntç with naçtrir гяпгог 
Mean IdU/BrdU LI 
6.9% (SD 1.8) 
6.7% (SD 9.9) 
6.2% (SD 11.0) 
3.1% (SEM 0.2) 
4.4% (SEM 0.5) 
5.2% (SD 7.2) 
3.7% (SEM 0.7) 
6.8% (SEM 0.3) 
4.8% (SEM 0.2) 
5.1% (SEM 0.6) 
7.3% (SD 2.4) 
6.5% (SEM 0.5) 
4 R % ЛЧП ч -η 
Ref. 
14 
45 
45 
19a 
42a 
45 
42a 
42a 
19a 
19a 
18 
19a 
44 
Corpus mucosa 3.6% (range 2.2-4.4) 43a 
Corpus mucosa of patients with 
Helicobacter pylori positive gastritis 6.0% (range 4.7-7.7) 43a 
Corpus mucosa after partial gastric resection 9.0% (range5.6-12.4) 43a 
Normal corpus mucosa of patients with 
gastric cancer 2.8% (SD 2.4) *• 
Gastric corpus and antrum mucosa Range 0.4-17% ^3 
Fundic mucosa of patients with early 
gastric cancer 6.4% (SD 1.5) 1θ 
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Table 3 (continued) 
Tissue Mean IdU/BrdU LI Ref. 
Patients with remnant stomachs (Billroth type II) 
Lesser curvature 5.8% (SD 0.2) 
Greater curvature 6.1 % (SD 2.4) 
Stomal area 9.8% (SD 2.1) 
Antrum mucosa with intestinal metaplasia 
Intestinal metaplasia in patients with 
gastric carcinoma 
Early gastric cancer 
Early gastric cancer with lymph 
node metastasis 
Early gastric cancer without lymph 
node metastasis 
Gastric cancer 
Gastric cancer 
Gastric cancer 
Gastric cancer 
Gastric cancer 
4.7% (SEM 0.3) 
8.9% (SD 9.5) 
8.1% (SD 3.3) 
18.2% (SD 6.6) 
13.9% (SD 7.8) 
Range 2.1 -45% 
Range 4.8-45.1% 
Range 2.3 - 43.2% 
11.9% (SD 5.8) 
15.6% (SD 10.1) 
19a 
45 
16 
17 
17 
4 
6a 
10a 
16 
45 
In vitro labelling 
between administration of IdU and resection of the tumor). This period of course 
is strongly dependent on eventual complications during operation, and 
unfortunately can not be planned strictly. IdU was injected 3 to 6 hours before 
resection of the tumor, and therefore in tumors with a short doubling time, 
differences in incubation time of IdU possibly could disturb correlation with 
MIB-1 LI. 
In conclusion, MIB-1 immunostaining of conventionally fixed and processed 
biopsy specimens of normal gastric mucosa, correlates closely with that of "in 
vivo" IdU labelling, and may be used as the method of choice for determining cell 
proliferation. In contrast, in gastric tumor specimens, MIB-1 LI does not correlate 
with the "in vivo" IdU labelling. Therefore, caution is needed in the interpretation 
of MIB-1 LI or"in vivo" IdU LI in gastrictumors, and it should not be used uncritically 
as markers of cell proliferation in stomach cancer. 
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Table 4 
Immunohistochemical determination of MIB-1 LI: data from literature. 
Tissue 
Gastric corpus and antrum mucosa 
Mucosa of patients with gastric cancer 
Normal mucosa 
Upper layer 
Middle layer 
Lower layer 
Low grade dysplasia 
Upper layer 
Middle layer 
Lower layer 
High grade dysplasia 
Upper layer 
Middle layer 
Lower layer 
Gastric carcinoma 
Areas of maximal tumor cell proliferation 
Mean MIB-1 LI 
Range 0 - 59% 
Areas randomly distributed over the whole tumor 
Areas located at the tumor invasion front 
0% 
68.1% 
0% 
16.3% 
32.7% 
21.7% 
57.2% 
52.8% 
26.6% 
51.3% 
43.2% 
37.2% 
Ref. 
39 
46 
47 
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Summary 
Resistance to chemotherapeutic agents is a major problem in the treatment of 
patients with gastric cancer. Several studies have indicated that many factors 
may play a role in the resistance of gastric cancer cells to cytotoxic drugs. The 
purpose of this study was to investigate the significance of glutathione (GSH), 
glutathione S-transferases(GSTs),P-170glycoprotein (Pgp), multidrug resistance 
associated protein (MRP) and cell proliferation as parameters for response and 
resistance to chemotherapy in patients with gastric cancer. 
In endoscopic biopsies of normal and malignant gastric tissue from 15 patients 
with gastric cancer treated with chemotherapy, the GSH content, GST activity, 
and levels of GST Alpha, Mu and Pi isoenzyme, Pgp and MRP were determined 
before start of chemotherapy, after2 courses of chemotherapy and after6 cycles 
of chemotherapy. Furthermore cell proliferation was determined in these biopsies 
after in vivo iododeoxyuridine (IdU) labelling. 
None of the above mentioned parameters were predictive for response to 
chemotherapy. After2 courses of chemotherapy there was an increase of median 
GSH content (367%) in patients with partial response (PR), whereas there was 
a decrease (43%) in patients with progressive disease (PD) (p<0.05). Median 
GST activity increased (257%) in patients with PR, and declined (31 %) in patients 
with PD (p<0.05). GST Pi showed a median increase of 326% in responding 
patients and a 59% decrease in progressive patients (p<0.05). There were no 
significant changes in GST Alpha and Mu. In patients with stable disease (SD) 
there were no significant changes in GSH/GST parameters. 
Because of the low expression of Pgp and MRP in both normal and malignant 
gastric mucosa, these parameters could only be considered to be present or 
absent. Because of the small study population and low expression levels no 
definite conclusion could be taken about the predictive value of these proteins. 
In conclusion, GSH and GST parameters, Pgp and MRP expression and IdU LI 
determined before start of chemotherapy were not predictive for response to 
chemotherapy. However, the differences of GSH and GST parameters between 
responding and progressive patients during treatment suggests a role for the 
GSH/GST system in the susceptibility of gastric tumor cells to chemotherapy. 
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Introduction 
Mortality from gastric cancer has declined world-wide. It nevertheless remains as 
a major form of cancer-related death. Surgery offers the only chance of cure at 
present. However, at diagnosis, 75% of patients have disseminated disease1. 
Even among the subgroup of patients who are able to undergo potentially curative 
resection, relapse is common. Therefore, improvement of outcome for this 
patient's group is only to be expected from chemotherapy. However, gastric 
cancers often are resistant to chemotherapeutic agents, which implies that only 
partial response is achieved or no effect at all is found. A better understanding 
of the mechanisms leading to drug resistance could indicate ways to more 
effective treatment. Therefore, it is essential to identify the factors that may 
contribute to resistance. To achieve this it is relevant to characterize and quantify 
several potential resistance mechanisms in both the tumor and the surrounding 
normal mucosa. 
Upon exposure to drugs from natural products, tumorcells can acquire resistance 
to structurally and functionally unrelated drugs. This type of drug resistance is 
called multidrug resistance. The classical form of multidrug resistance is caused 
bytheP-170 glycoprotein (Pgp) encoded by the human MDR1 gene. This protein 
is inserted in the plasma membrane and acts as an ATP-driven drug efflux 
pump23. The presence of Pgp in tissues such as colon, liver, kidney and at the 
blood-brain barrier suggests that it has a normal physiological role in defense 
againstxenobiotics2. Increased expression of theMDRI gene has been detected 
in various human tumors originating from tissues that normally express Pgp, as 
well as in tumors originating from cells that do not express Pgp, such as myelomas 
and sarcomas2 "5. Although Pgp overexpression is likely to contribute to multidrug 
resistance in at least some tumor types, it has become evident that alternative, 
non-Pgp-mediated mechanisms of multidrug resistance exist Many cell lines 
selected for resistance do not contain increased levels of Pgp but nevertheless 
are resistant to a broad range of natural product drugs6"8. Several of these cell 
lines9-14 contain high levels of the multidrug resistance associated protein (MRP), 
first described by Cole et a/.9. Like Pgp, MRP seems to be a plasma membrane 
located drug pump that extrudes drugs from the cell by mediating the ATP-
dependent membrane transport of glutathione S-conjugates and amphophilic 
organic anions1516. 
In the process of chemotherapy resistance the glutathione S-transferases 
(GSTs) may also be of significance. The GSTs constitute a remarkably versatile 
family of enzymes involved in the cellular detoxification of xenobiotics. The 
enzymes have in common the ability to catalyze the conjugation of various 
electrophilic compounds with glutathione (GSH), a reaction which detoxifies 
compounds by covalent attachment of GSH to potentially harmful electrophilic 
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groups. The role of GSTs in protecting healthy cells from cytotoxic insult is well-
established17 1B. There is increasing evidence suggesting that malignant cells may 
also be capable of using these enzymes for protection against many cytotoxic 
agents1924. Based on structural, physicochemical, enzymatic, and immunological 
properties cytosolic GSTs are divided into four classes: Alpha, Mu, Pi and 
Theta25 26. GST Pi and Alpha are the predominant subclasses detected in gastric 
tissue, in both normal mucosa and carcinomas27 2B. 
Most anticancerdrugsshowgreatertoxicity for rapidly proliferating cells, suggesting 
an explanation for the greater responsiveness of rapidly growing tumors to 
chemotherapy and allows partly understanding of the problem of resistance. In 
gastriccancerthereare no data about cell proliferation in relation to chemotherapy 
sensitivity. 
The purpose of this study was to investigate the significance of GSH, GSTs, Pgp, 
MRP and cell proliferation as parameters for réponse and resistance to 
chemotherapy in patients with gastric cancer. To achieve this, in endoscopic 
biopsies of malignant and normal gastric tissue, determination of the GSH 
content, the overall GST activity, the GST isoenzymes class Alpha, Mu and Pi and 
Pgp expression was performed before start of chemotherapy. These investigations 
were repeated aftertwo cycles of chemotherapy in all patients, and after six cycles 
of chemotherapy in responding patients and in patients with stable disease. 
Immunohistochemical determination of GST class Alpha and Pi and of 
iododeoxyuridine labelling index(ldL) LI), determined afterin vivo IdU incorporation, 
was also performed. 
Patients and methods 
Patients and tumor samples 
In 15 patients with gastric cancer treated with chemotherapy, consisting of 5-
f luorouracil, epirubicin and methotrexate (FEMTX) or FEMTXP (FEMTX combined 
with cisplatin), endoscopic biopsies of normal and malignant gastric tissue were 
taken before start of chemotherapy. In all patients 2 weeks after the second cycle 
of treatment and in responding patients and in patients with stable disease this 
was repeated 2 weeks after the 6th course of chemotherapy. 
Response was defined as a reduction greaterthan 50% in the sum of the products 
of the largest perpendicular diameters of the measurable lesions. Progression 
was defined as 25% increase in the sum of the products of the perpendicular 
diameters of indicator lesions, or appearance of any new lesions. Patients not 
qualifying for response or progression were classified to have stable disease. 
Tumor stage was classified according to the criteria of the American Joint 
Committee on Cancer29. 
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IdU was administered as a 15 minutes intravenous infusion, 200 mg/m2 (maximum 
dose, 400 mg), 4 hours before taking biopsies. No IdU related side effects were 
seen. 
Specimens of normal mucosa were taken from areas at least 5 cm away from the 
tumor. Biopsies of tumor tissue were taken from non-necrotic areas of the tumor. 
Aftercollection of biopsies, 3 specimens of both normal and malignanttissue were 
quickly frozen in liquid nitrogen and stored at -80°C until required. Two samples 
of normal and neoplastic gastric tissue used for immunohistochemical analyses 
were washed in cold phosphate buffered saline (PBS) and fixed immediately in 
4% paraformaldehyde. 
The study was approved by the local Medical Ethical Review Committee. 
Informed consent was obtained from each patient. 
Biochemical quantification of GST enzyme activity and GST subclasses 
Cytosolic fractions were prepared as described before30. Protein concentrations 
were determined according to Lowry et a/.31. GST enzyme activity was assayed 
by the method of Habig et al.2,2 using 1-chloro-2,4-dinitrobenzene as substrate. 
Cytosols were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and subsequentto Western blotting. Western blots 
were incubated with monoclonal antibodies against GST Alpha, Mu and Pi and 
the specific binding of the monoclonal antibodies to their antigens was detected 
as previously described30. Staining intensity was quantified by laserdensitometry 
(Ultroscan XL, LKB, Bromma, Sweden) using purified GSTs as marker proteins. 
Detection limit of this method is approximately 40 ng/mg protein and within-assay 
and between-assay variation is 10-15%. Class Alpha antibodies react against 
GST A1-1, GST A1-2 and GST A2-230, class Mu antibodies recognize GST Mía-
la, GST M1a-1b and GST M1b-1b3334, and class Pi antibodies are directed 
against GST P1-135. 
As the expression of GST Mu was always very low or absent, no quantification 
was possible. So the expression of GST Mu was considered to be present or 
absent. 
Immunohistochemical detemnination of GST class Alpha and Pi 
Immunohistochemical determination of GST class Alpha and Pi was performed 
as described before28. In short, the slides were incubated overnight at 4°C with 
primary antibodies against GST class Alpha (monoclonal antibody), as developed 
by Peters eí al.30, and GST class Pi (polyclonal antibody; Biotrin International, 
Dublin, Ireland). Subsequently an incubation with peroxidase conjugated rabbit-
anti-mouse immunoglobulin (Dakopatts, Glostrup, Denmark) or peroxidase 
conjugated swine-anti-rabbit immunoglobulin (Dakopatts) was performed in case 
of GST Alpha or Pi immunodetection, respectively. In order to enhance the 
intensity of the final staining a third incubation step was used: peroxidase 
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conjugated swine-anti-rabbit immunoglobulin (Dakopatts) for GST class Alpha 
and peroxidase conjugated rabbit-anti-mouse immunoglobulin (Dakopatts) for 
GST class Pi. Staining was performed using 0.1 % 3,3-diaminobenzidine (Sigma 
Chemical Company, St. Louis, MO, USA). The slides were counterstained with 
haematein. 
Both the intensity of staining and the proportion of stained cells were scored by 
two independent individuals. Staining was graded as follows: (0) <1 percent 
stained cells, (1)1-5 percent stained cells, (2) 6-25 percent stained cells, (3) 26-
50 percent stained cells, (4) 51-75 percent stained cells, (5) >75 percent stained 
cells. The distribution of staining was assessed by scoring tumor cells and normal 
mucosa cells separately. 
PQP 
Plasma membrane-enriched fractions (12,000g pellets; 80 \ig protein) were 
subjected to SDS-PAGE, Western blotting, and subsequent incubation was 
performed using a monoclonal antibody against the Pgp (C219; Centocor, 
Malvern, PA). Biotin-conjugated rabbit anti-mouse serum (Dakopatts) was used 
as the second antibody. Detection was performed using the tyrosin biotin 
detection system36. As standard the 12,000 g pellet (39 pg protein) from the MCF-
7 Adriamycin resistant breast cancer cell line was used. 
MRP 
Plasma membrane-enriched fractions (12,000g pellets; 80 pg protein) were 
subjected to SDS-PAGE, Western blotting, and subsequent incubation was 
performed using a monoclonal antibody against the MRP (MRPm6, kindly 
donated by Dr. RJ Scheper, Amsterdam, The Netherlands). Biotinilated rabbit 
anti-mouse serum (Dakopatts) was used as second antibody. Detection was 
performed using the tyrosin biotin detection system36. As standard the 12,000 g 
pellet (10 μg protein) from the GLC4 lung cancer cell line (kindly donated by Prof. 
Dr. EGE de Vries, Groningen, The Netherlands) was used. 
IdU LI 
Tissue sections were dewaxed in xylol, rehydrated in ethanol and immersed in 
methanol with 2% hydrogen peroxide for 10 min. to blockendogenous peroxidase 
activity. Subsequently, the sections were treated with 0.05 mg/ml pepsin 
(Boehringer, Mannheim, Germany) diluted in PBS for 30 minutes at 37°C. The 
slides were hydrolysed in 2 M HCl at 37°C for 18 min. and then neutralised in boric 
acid buffer. Subsequently, the slides were incubated overnight at 4°C with primary 
antibody against IdU (developed at the department of Pathology, University 
Hospital Nijmegen), diluted 1:40,000 in PBS containing 2% normal rabbit serum 
(NRS) and 2% bovine serum albumin (BSA) (Buffer A). Biotinylated rabbit 
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secondary antibody against mouse immunoglobulins (Dakopatts) diluted 1:100 
in buffer A was applied for 45 min. at room temperature. Staining was performed 
using 0.1% 3,3-diaminobenzidine in PBS containing 0.01% hydrogen peroxide 
as peroxidase substrate. The slides were counterstained with haematein. 
Between each step the sections were washed in PBS three times each for 5 min. 
The slides were evaluated by two independent observers, using a standard light 
microscope with a X40 objective. The proportion of cells showing staining was 
scored as follows: (a) <1 percent stained cells, (b) 1-2.5 percent stained cells, (c) 
2.5-5 percent stained cells, (d) 5-10 percent stained cells, (e) >10 percent stained 
cells. 
Statistical analysis 
To analyse the association between the degree of response to chemotherapy 
(response, stable disease or progressive disease) and the pattern over time of 
the biochemical parameters a general linear mixed model is assessed. In this 
model the dependence structure of the repeated measurements within a subject 
is accounted for. The difference in these biochemical parameters before start of 
chemotherapy between the three response groups can also be addressed in this 
model. To analyse relative changes over time, the data are logarithmiccally 
transformed before analysis. Changes in the biochemical parameters are 
presented as changes in the median values. The p-values are obtained with the 
restricted maximum likelihood approach. 
To compare the presence of MRP expression in malignant tissue with the 
presence in adjacent normal tissue the McNemar test is applied. The IdU LI in 
malignant tissue is compared with the IdU LI in adjacent normal tissue and 
classified as follows: + = a higher score in malignant tissue, 0 = the same score, 
- = a lower score. The marginal frequencies of this classification before start of 
chemotherapy and after 2 courses are compared with the marginal homogenity 
test. 
The immunohistochemical scores for GST Pi, GST Alpha and IdU before start of 
chemotherapy in the three response groups are compared by the Kruskal Wallis 
test. Because of small numbers the exact p-values are calculated for these 
nonparametric tests. 
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Results 
Patients characteristics 
The characteristics of the 15 patients treated with chemotherapy for advanced 
gastric cancer (stage III and IV) are presented in Table 1. Three patients showed 
partial response (PR) to chemotherapy, 7 patients showed stable disease (SD), 
and 5 patients had progressive disease (PD). Median survival was 8 months 
(range 5-13). 
Table 1 
Characteristics of patients (n=15) with advanced gastric cancer, treated with 
chemotherapy. 
Sex 
Male 
Female 
Age (years) 
Median 
Range 
Tumor Stage 
Stage I 
Stage II 
Stage III 
Stage IV 
Treatment 
FEMTX 
FEMTX-P 
Response 
Complete Response 
Partial Response 
Stable Disease 
Progressive Disease 
Survival (months) 
Median 
Range 
13 
2 
60 
31 -69 
0 
0 
6 
9 
7 
8 
0 
3 
7 
5 
8 
5-13 
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Biochemical quantification of GST enzyme activity and GST subclasses 
GST enzyme activity and GST isoenzymes were determined in normal and 
neoplastic gastric tissue, taken before start of chemotherapy, after 2 courses of 
chemotherapy, and in patients with SD or PR also after6 courses of chemotherapy. 
Data on GSH, GST activity and GST Alpha and Pi expression are summarized 
in Table 2. 
Table 2 
Change in median values of GSH and GST in gastric carcinoma during and 
after treatment with chemotherapy, obtained by biochemical analyses. 
Median values in each group before start of chemotherapy were considered as 
100%. 
GSH content (%) 
PR (n=3) 
SD (n=7) 
PD (n=5) 
GST activity (%) 
PR (n=3) 
SD (n=7) 
PD (n=5) 
GST Alpha (%) 
PR (n=3) 
SD (n=7) 
PD (n=5) 
GST Pi (%) 
PR (n=3) 
SD (n=7) 
PD (n=5) 
Before 
start 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
After 2 
courses 
367 
106 
57 
257 
160 
69 
232 
41 
114 
326 
101 
41 
After 6 
courses 
196 
126 
105 
111 
117 
109 
151 
116 
89 
146 
82 
70 
Abbreviations: PR = partial response; SD = stable disease; PD = progressive 
disease; η = number of patients in each group 
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Before start of chemotherapy there were no significant differences in values of 
GSH and GST parameters in patients with PR, SD or PD. 
In gastric carcinoma after 2 courses of chemotherapy there was an increase of 
median GSH content of 367% in patients with PR, whereas there was a decrease 
of 43% in patients with PD. However, the pattern of changes over time in GSH 
content was not significantly associated with the degree of response to 
chemotherapy (p=0.310). 
The pattern of changes over time in GST activity differed significantly between 
the three response groups (p=0.04). Median GST activity enhanced by 257% in 
patients with PR, and declined 31% in patients with PD (p<0.05). For GST Pi, the 
pattern over time differed between the three groups (p=0.07), due to a median 
increase of 326% in responding patients compared with a 59% decrease in 
progressive patients (p<0.05). There was no significant change in GST Alpha. 
The same tendency was seen when GSH/GST parameters in malignant tissue 
were compared to values in adjacent normal tissue. 
Presenceof GST Mu(Table3) was detectable in3out of 3(100%), 3out of 7 (43%) 
and 3 out of 5 (60%) specimens of both normal and malignant tissue of patients 
with PR, SD, and PD respectively, and did not change during chemotherapy. 
Immunohistochemical determination of GST class Alpha and Pi 
The median values of GST Alpha and Pi expression in normal and malignant 
gastric tissue in patients with PR, SD or PD are given in Table 4. Before start of 
chemotherapy the expression of GST Alpha was lower in the carcinomas as 
compared to the adjacent normal mucosas (p<0.05), whereas there was no 
significant difference in GST Pi between normal and malignant gastric mucosa 
(sign test). 
The expression of GST Alpha or Pi before start of chemotherapy was not 
significantly different in the three response groups. 
Pgp 
In all tissue samples the expression of Pgp was very low (just above detection limit) 
or absent. Therefore no detailed quantification of Pgp expression was possible. 
The expression of Pgp was considered to be present or absent. Data about Pgp 
expression are given in Table 3. 
Pgp was present in all normal gastric tissue specimens and in 80% of gastric 
carcinoma specimens. Conclusions about the predictive value of Pgp expression 
could not be made in this small study population. 
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Table 3 
Expression of GST Mu, Pgp and MRP in normal (N) and malignant (M) gastric 
tissue before, during and after treatment with chemotherapy. 
GST Mu expression 
PR (n=3) 
SD (n=7) 
PD (n=5) 
Pqp expression 
PR (n=3) 
SD (n=7) 
PD (n=5) 
MRP expression 
PR (n=3) 
SD (n=7) 
PD (n=5) 
Before start 
N 
3/3 
3/7 
3/5 
3/3 
7/7 
5/5 
3/3 
3/7 
3/5 
M 
3/3 
3/7 
3/5 
3/3 
5/7 
4/5 
0/3 
1/7 
1/5 
After 2 
courses 
N 
3/3 
3/7 
3/5 
3/3 
7/7 
5/5 
3/3 
4/7 
2/5 
M 
3/3 
3/7 
3/5 
3/3 
5/7 
5/5 
1/3 
2/7 
1/5 
After 6 
courses 
N 
3/3 
3/7 
3/3 
3/3 
7/7 
3/3 
3/3 
5/7 
2/3 
M 
3/3 
3/7 
3/3 
3/3 
7/7 
3/3 
1/3 
3/7 
1/3 
Abbreviations: PR = partial response; SD = stable disease; PD = progressive 
disease; η = number of patients in each group 
MRP 
Because of the low expression of MRP in both normal and malignant gastric 
mucosa, MRPcould only be considered to be present orabsent. Data about MRP 
expression are given in Table 3. 
Before start of chemotherapy MRP was present in 9 of 15 normal tissue samples, 
whereas it was present in 2 of 15 malignant gastric tissue specimens (McNemar 
test, p<0.05). In tumors there seems to be a tendency to upregulate the 
expression of MRP during treatment, but because of the small study population 
and low expression levels no definite conclusions can be taken about the 
predictive value of MRP expression or about the changes in time. 
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Table 4 
Median scoring after immunohistochemical staining for GST Alpha and Pi in 
normal (N) and malignant (M) gastric tissue before, during and after treatment 
with chemotherapy. 
GST Alpha 
PR (n=3) 
SD (n=7) 
PD (n=5) 
GST Pi 
PR (n=3) 
SD (n=7) 
PD (n=5) 
Before start 
N 
1 
2 
2 
2 
2 
2 
M 
0 
1 
0 
3 
2 
1 
After 2 
courses 
N 
3 
1 
1 
1 
1 
2 
M 
2 
2 
0 
3 
2 
2 
After 6 
courses 
Ν M 
1 0 
1 1 
1 0 
2 2 
1 2 
1 4 
Abbreviations: 
PR = partial response; SD = stable disease; PD = progressive disease; 
η = number of patients in each group 
(0) <1 percent stained cells, (1) 1-5 percent stained cells, (2) 6-25 percent 
stained cells, (3) 26-50 percent stained cells, (4) 51-75 percent stained cells, 
(5) >75 percent stained cells 
IdU LI 
Data about IdU LI are given in Table 5. 
The IdU LI in the tumors before start of chemotherapy was not significantly 
different in the three response groups. 
When IdU LI in malignant tissue was compared to that in adjacent normal tissue, 
after 2 courses of chemotherapy there was an increase of IdU LI (marginal 
homogenity test, p=0.02), with respect to levels before start of chemotherapy. 
After 6 courses of chemotherapy there was no difference. 
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Table 5 
Median scoring of IdU LI after immunohistochemical staining in normal (N) and 
malignant (M) gastric tissue before and after treatment with chemotherapy. 
IdU LI 
PR (n=3) 
SD (n=7) 
PD (n=5) 
Before start 
Ν M 
с с 
с с 
с с 
After 2 
courses 
Ν 
с 
с 
с 
M 
d 
d 
d 
After 6 
courses 
Ν M 
с d 
b d 
с с 
Abbreviations: 
PR = partial response; SD = stable disease; PD = progressive disease; 
η = number of patients in each group 
(a) <1 percent stained cells, (b) 1-2.5 percent stained cells, (c) 2.5-5 percent 
stained cells, (d) 5-10 percent stained cells, (e) >10 percent stained cells 
Discussion 
In our study GSH and GST parameters in gastric cancer were not predictive for 
response to chemotherapy. Data from the literature about the predictive value of 
GST parameters are controversial. In two studies of patients with leukemia total 
GST activity37 and specific expression of GST Pi38 showed a correlation with 
clinical response. However, in another study of patients with leukemia no 
correlation between GST activity and response to chemotherapy was observed39. 
In a study of Bai et a/."0 the expression of GST Pi in patients with non-small cell 
lung carcinoma was significantly related to response to cisplatin-based 
chemotherapy. Three studies in patients with ovarian tumors indicated that low 
levels of GST Pi were prognostic for response to chemotherapy and prolonged 
survival41"13. Incontrasi, GST activity and isoenzyme distribution, orimmunostaining 
of GST Pi did notpredict response to chemotherapy in fourotherseries of patients 
with ovarian cancer44"17. In two studies, concerning node-positive breast cancer 
patients treated with adjuvant chemotherapy, the pretreatment expression levels 
of GSTs had no predictive value48·49. Furthermore, in human soft tissue sarcomas 
no correlation was found between GST Pi expression and response to 
chemotherapy50. Based on these studies, it can be concluded that the predictive 
value of GSH and GST parameters determined before treatment with 
chemotherapy is at least questionable. 
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However, in our present study, the differences of GSH, GST activity and GST Pi 
expression between responding and progressive patients during chemotherapy 
treatment (after two cycles) suggests a role for the GST/GSH system in the 
susceptibility of gastric tumor cells to chemotherapy, since the values are much 
higher in responding patients. This is an unexpected finding, because in 
responding patients lower values were expected. Hypothetically, high values are 
correlated with rapid detoxification of chemotherapeutics and consequently little 
effects on tumor growth can be expected. However, since tissue samples were 
taken 2 weeks after administration of chemotherapy, the high GSH/GST values 
could be indicative for an overshoot mechanism, as a reaction on the treatment 
with chemotherapeutics. 
Pgp is a protein strongly associated with multidrug resistance to certain cytostatic 
drugs. It is expressed in many human cancers and normal tissues. We found 
expression of Pgp in all normal gastrictissue samples, which is in accordance with 
data from Van der Valk et a/.51, who found Pgp expression in cells with secretory 
and excretory functions, such as the gastrointestinal epithelium (including the 
stomach), suggesting a physiological role in removal of potential toxic substances. 
Pgp expression in clinical tumor samples has been extensively studied in order 
to determine its potential role as a predictor of drug responsiveness. Several 
studies showed an association between Pgp expression and lack of 
chemotherapeutic response352. However, in our opinion the best evidence for 
Pgp to be involved in clinical drug resistance, is the demonstration of an increase 
in Pgp tumor levels during acquired resistance. Therefore we determined Pgp 
expression levels before start of chemotherapy, after2 courses of chemotherapy 
and after 6 courses of chemotherapy. We found Pgp expression in 80% of 
untreated gastric tumors. In all cases Pgp was present at very low levels, just 
above the detection limit. During treatment there was no detectable increase in 
Pgp expression. Because of the small study population and the low expression 
levels no definite conclusion can be taken, but it seems that in gastric cancer 
treated with 5-fluorouracil, epirubicin, methotrexate and cisplatin, Pgp does not 
play an important role in the sensitivity of the tumor cells towards these drugs. In 
addition, Pgp expression levels as determined before start of chemotherapy were 
not predictive for response. 
MRP is a recently identified protein, that may cause resistance of cells to a wide 
variety of drugs, similarto those observed for Pgp mediated multidrug resistance. 
MRP gene expression has been reported in haematological malignancies and 
solid tumors16, including gastric cancer5354. In ourstudy we found MRP expression 
more frequently in normal gastric mucosa than in gastric carcinoma, suggesting 
a role as detoxifying mechanism in normal physiology. There was a tendency for 
higher MRP levels in the tumor after treatment, but due to the small group of 
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patients in our study, no conclusion can be made about the predictive value of 
MRP expression. 
We studied the relation between cell proliferation and susceptibility to chemotherapy 
using in vivo IdU labelling. No correlation was found between IdU LI and response 
to chemotherapy. However, after 2 courses of chemotherapy an increase of IdU 
LI was found in malignant tissue compared to normal tissue, which could indicate 
the development of acquired resistance. Whether this increase is of clinical 
importance is a topic for further research. 
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Patients with gastric cancer have a poor prognosis. Of all patients with newly 
diagnosed disease 5 year survival ranges from 10 to 15%. Many patients present 
with advanced metastatic cancer or locally advanced tumors, in which potentially 
curative surgery is impossible. Even after potential curative resection relapse is 
common. Therefore, the use of chemotherapy in gastric cancer has been a 
subject of great interest. Unfortunately, only approximately half of the patients 
with gastric carcinomas initially respond to chemotherapy, whereas half of the 
tumors are primarily resistant. Of the responding tumors, the majority acquires 
secondary resistance. The mechanism of resistance is basically unknown. There 
is increasing evidence suggesting that malignant cells may be capable of using 
glutathione S-transferases (GSTs) - a family of enzymes involved in the 
detoxification of xenobiotics - for protection against antineoplastic agents. The 
topic of this thesis was to study the role of GSTs as parameter for prognosis and 
for respons to chemotherapy in patients with gastric cancer. 
Chapter 1: General introduction 
In chapter 1 an outline of the thesis is presented. 
Chapter 2: Chemotherapy of gastric cancer 
In chapter 2 an overview of the literature concerning chemotherapy of gastric 
cancer is described. The results of single agent chemotherapy are presented. As 
complete responses with monotherapy are very uncommon and responses are 
generally of brief duration and without a significant impact on survival, it is 
concluded that single agent chemotherapy can not be recommended as a clinical 
routine. 
Combination chemotherapy regimens in gastric cancer have been derived from 
active single agents with different working mechanisms. Several combination 
regimens are described. Approximately half of the patients with advanced gastric 
cancer may benefit from such combination chemotherapy by amelioration of 
symptoms and prolongation of survival. The median survival of responding 
patients is 9 -12 months. 
Moreover the role of adjuvant and neo-adjuvant chemotherapy is discussed. It is 
concluded that adjuvant chemotherapy has no proven benefits, whereas phase 
II trialsof neoadjuvant chemotherapy indicate that thisapproachisvery encouraging 
and should be explored further. 
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Chapter 3 : Glutathione S-transferases 
In chapter 3 some details about the glutathione S-transferase (GST) enzyme 
system aregiven. The GSTsconstituteafamily of enzymes involved inthe cellular 
detoxification of xenobiotics. These enzymes protect healthy cells from (cyto)toxic 
insults. They catalyze the conjugation of various electrophilic compounds with 
glutathione, a reaction which detoxifies compounds by covalent attachment of 
glutathione to potentially harmful electrophilic groups. 
The GSTs are divided into four classes: Alpha, Mu, Pi, and Theta. The level of 
expression of GST isoenzymes is cell and tissue specific. Increased expression 
of GST class Pi has been found in many tumors. The biological significance of 
this finding is still unclear, but it was suggested that increased expression of GST 
Pi may be a marker of malignant transformation. 
The role of GST Pi as prognostic marker is also discussed. High GST Pi 
expression was negatively correlated with survival in patients with colorectal 
tumors, renal cell carcinomas, soft tissue sarcomas and breast cancer, suggesting 
a possible relationship between high GST Pi expression and bad prognosis. 
There is evidence that malignant cells may be capable of using GSTs for 
protection against antineoplastic agents. An overview is given of preclinical and 
clinical studies, concerning the role of GSTs in anticancer drug resistance. Many 
preclinical studies showed a correlation between GSTs and drug resistance, 
however the results of clinical studies are equivocal. Therefore the role of GSTs 
in anticancer drug resistance is still unclear. 
Chapter 4: Cell proliferation 
Cell kinetic data are important indicators of clinical behavior in many types of 
cancer. In chapter4 a variety of methods for determination of cellular proliferation 
are described. The advantages and disadvantages of each method are 
summarized. Moreover, an overview is given of data from the literature concerning 
the prognostic value of proliferative activity in gastric cancer. It is concluded that 
there is considerable evidence that assessment of proliferation activity provides 
usefull information and may be of prognostic significance. However, in the near 
future multivariate analyses should be performed to establishwhetherproliferation 
is an independent prognostic variable. 
Chapter 5: Immunohistochemical determination of GSTs 
The role of GSTs as prognostic parameter in gastric cancer and their role in 
anticancer drug resistance is an important issue of this thesis. To better 
understand these mechanisms, knowledge about the distribution of GSTs in 
normal and malignantgastrictissue is necessary. In chapter5 immunohistochemical 
expression of GST class Alpha and Pi was examined in normal and malignant 
gastric tissue. Expression of GST Alpha and Pi was observed in 47 and 100 
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percent of the tumors, respectively. The distribution of GST Alpha and Pi in 
different cell types of the normal mucosa was described. It was concluded that 
mucous cells showed staining for GST Alpha and Pi in 88 and 97 percent, parietal 
cells in 93 and 67 percent, and chief cells in 82 and 30 percent of the sections in 
which they were present, respectively. 
Chapter 6: Comparison of biochemical and immunohistochemical expression of 
GSTs 
The distribution of GSTs in normal and malignant gastrictissue can be determined 
biochemically or immunohistochemically. In Chapter 6 data on expression of 
GSTs obtained by biochemical as well as immunohistochemical methods were 
compared. No statisticallysignifi cant correlation was found comparing biochemical 
and immunohistochemical determination of GST class Alpha and Pi. The 
possible reasons for this discrepancy are discussed. 
Chapter 7: Correlation of GSTs with survival 
In this chapterthe relationship between GSTs and tumor and patient characteristics, 
including overall survival, were studied retrospectively in normal and malignant 
gastric tissue from 49 patients with gastric cancer, who were treated surgically. 
In this study GST parameters were found not to be related to tumor stage, 
localization and diameter of the tumor, number of eosinophils in the tumor, 
presence of intestinal metaplasia in normal gastric mucosa, or gender and age 
of the patient. After optimal dichotomization of GST parameters, uni- and 
multivariate analyses were performed in order to reveal possible associations 
between these parameters and overall survival. It was found that high levels of 
GST Pi in both normal and malignant gastric tissue and the presence of GST Mu 
in both kind of tissue specimens had a favourable significant prognostic value on 
overall survival, independent from the clinicopathological parameters. 
Chapter 8: Comparison of "in vivo" iododeoxyuridine labelling index (IdULI) and 
MIB-1 LI 
In chapter 8 two different methods for assessment of cellular proliferation are 
compared. Intissue specimens from 20 patients with gastric cancerthe proliferative 
activity was determined after "in vivo" labelling with IdU and after staining with the 
MIB-1 antibody. In normal gastric tissue a significant correlation was found 
between both proliferation markers. However, in gastric carcinoma MIB-1 
immunostaining did not correlate with IdU labelling. Therefore, caution is needed 
in the interpretation of MIB-1 immunostaining or IdU labelling in gastric tumors. 
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Chapter 9: The role of glutathione (GSH), GSTs, P-170 glycoprotein (Pgp), 
multidrug resistance associated protein (MRP) and IdLI LI in drug resistance of 
gastric cancer 
Gastric cancers are often resistant to chemotherapeutic agents. A better 
understanding of the mechanisms leading to drug resistance could indicate ways 
to more effective treatment. Therefore, it is essential to identify the factors that 
may contribute to resistance. 
In chapter 9 the significance of GSH, GSTs, Pgp, MRP and IdU LI as parameters 
for response and resistance to chemotherapy in patients with gastric cancerwere 
investigated. In 15 patients with gastric cancerthe expression of GSH, GSTs, Pgp 
and MRP as well as IdU LI were determined in endoscopic biopsies of both normal 
and malignant gastric tissue, obtained before start of chemotherapy, after 2 
cycles of chemotherapy and after 6 cycles of chemotherapy. None of the above 
mentioned parameters were found predictive for response to chemotherapy. 
However, during anticancer drug treatment differences were found in GSH 
content, GST activity and GST Pi expression between responding and progressive 
patients, suggesting a role for the GST/GSH system in the susceptibility of gastric 
tumor cells to chemotherapy. 
General conclusions and recommendations for further research 
In a tumor with a poor prognosis - like gastric cancer- prognostic parameters are 
of great importance. We found that biochemically determined GST parameters 
were of independent predictive value for prognosis. Therefore, it would be 
worthwhile to perform a prospective study on the prognostic value of GSTs in a 
larger study population. 
In the literature there is increasing evidence that high GST Pi expression may be 
a marker of malignant transformation. Therefore it would be a subject of great 
interest to investigate the levels of GSTs in premalignant conditions of the 
stomach, such as atrophic gastritis. 
In this thesis cell proliferation in gastric cancer was studied using "in vivo" IdU 
labelling and with "in vitro" staining using the MIB-1 antibody. As is described in 
chapter4 a variety of methods are used to measure the percentage of proliferating 
cells. Comparison of different proliferation markers has given contradictory 
results. In many studies a good correlation between two different markers was 
found, however in other studies no significant correlation between different 
proliferation markers could be detected. In our study, we found a significant 
correlation between "in vivo" IdU LI and MIB-1 LI in normal gastric tissue, but not 
in malignant tissue. In the future more extensive research is necessary to unravel 
the interrelationships between the various methods of determining cellular 
proliferation. 
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The role of GSH, GSTs, Pgp, MRP and cell proliferation as parameters for 
response or resistance to chemotherapy in gastric cancer was studied. None of 
the parameters had a predictive value. However, the study was performed in only 
a small and heterogenous group of patients. In orderto address this issue a larger 
multicenter study should be performed. 
The topic of this thesis was to study the role of GSTs as parameter for prognosis 
and for response to chemotherapy in patients with gastric cancer. It can be 
concluded that in our studies biochemically determined GST parameters were of 
independent prognostic value for overall survival in patients with gastric cancer, 
who were treated surgically. However no significant correlation was found 
between GST parameters and response to chemotherapy. 
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Patiënten met een maagcarcinoom hebben een slechte prognose. De 5-jaars 
overleving varieert in verschillende studies van 10 tot 15%. Wanneerde diagnose 
maagcarcinoom wordt gesteld, is er vaak sprake van locale doorgroei of 
gemetastaseerde ziekte, zodat curatieve chirurgie niet mogelijk is. Bovendien 
treedt er na een curatieve resectie vaak tumor recidief op. Daarom is chemotherapie 
van het maagcarcinoom een onderwerp dat in de belangstelling staat. De 
resultaten van cytostatische behandeling van het maagcarcinoom zijn echter 
vaak teleurstellend. Slechts ongeveerde helft van de patiënten toont een goede 
respons op chemotherapie, terwijl de andere patiënten tumoren hebben die 
primair resistent zijn tegen chemotherapie. Van de patiënten, die aanvankelijk 
goede reactie vertonen op chemotherapie, wordt de meerderheid in tweede 
instantie alsnog resistent. Het werkingsmechanisme van de chemotherapie 
resistentie is grotendeels onbekend. Er zijn aanwijzingen dat maligne cellen 
gebruik maken van een enzymsysteem, namelijk de glutathion S-transferases 
(GSTs), om zich te beschermen tegen chemotherapeutica. GSTs zij η zogenaamde 
detoxificatie-enzymen, die de cel beschermen tegen schadelijke stoffen. Zij zijn 
bovendien in staat cytostatica af te breken. 
Het onderwerp van dit proefschrift is de rol van GSTs bij het maagcarcinoom te 
bestuderen, enerzijds als parametervoorde prognose, anderzijds als parameter 
voor de respons op chemotherapie. 
Hoofstuk 1: Algemene inleiding 
In hoofdstuk 1 wordt een overzicht gegeven over de opzet van het proefschrift. 
Hoofdstuk 2: Chemotherapie 
In hoofdstuk 2 wordt een overzicht gegeven betreffende chemotherapie bij het 
maagcarcinoom. De resultaten van monotherapie zijn weinig bemoedigend. 
Complete responses zijn zeldzaam en kortdurend, verlenging van de overleving 
wordt niet bereikt. Daarom lijkt er in de praktijk geen rol te zijn voor monotherapie. 
Op grond van ervaring met monotherapie zijn verschillende combinatie 
chemotherapie schema's ontwikkeld. In hoofdstuk2 worden de resultaten van de 
belangrijkste schema's gepresenteerd. Ongeveerde helft van de patiënten met 
een irresectabel maagcarcinoom heeft profijt van behandeling met combinatie 
chemotherapie, ofwel doordat ervermindering van klachten optreedt, ofwel door 
verlenging van overleving. De mediane overleving van patiënten, die respons 
vertonen op chemotherapie is 9 -12 maanden. 
Tenslotte worden de resultaten van adjuvante en neo-adjuvant chemotherapie 
beschreven en bediscussieerd. Thans is er geen rol vooradjuvante chemotherapie, 
daar dit geen verbetering van de overleving bewerkstelligt. Trials met neo-
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adjuvante chemotherapie daarentegen lijken veelbelovend. Verder prospectief 
gerandomiseerd onderzoek zal moeten uitwijzen, of er in de toekomst plaats is 
voor neo-adjuvante chemotherapie bij het resectabele maagcarcinoom. 
Hoofdstuk 3: Glutathion S-transferases 
In hoofdstuk 3 wordt een overzicht gegeven van het glutathion S-transferase 
(GST) enzym systeem. De GSTs vormen een familie van enzymen, die betrokken 
zijn bij de ontgiftiging van toxische stoffen. Zij beschermen gezonde cellen tegen 
(cyto)toxische middelen, doordat zij als katalysator functioneren bij een reactie 
waarbij potentieel schadelijke electrofiele groepen worden geconjugeerd met 
glutathion. 
De GSTs worden verdeeld in 4 klasses, namelijk Alpha, Mu, Pi, en Theta. De 
expressie van de GST isoenzymen varieert in de verschillende weefsels en 
celtypes. In vele tumoren is de expressie van GST Pi toegenomen. De betekenis 
hiervan is nog onduidelijk, maar het suggereert dat een toegenomen GST Pi 
expressie een marker is voor maligne transformatie. 
Tevens wordt de rol van GST Pi als prognostische marker bediscussieerd. Bij 
patiënten meteen coloncarcinoom, niercarcinoom, sarcoomen mammacarcinoom 
werd een negatieve correlatie gevonden tussen hoge GST Pi expressie en 
overleving. 
Op grond van de gegevens uit de literatuurzijn eraanwijzingen, dat maligne cellen 
zich m.b.v. de GSTs beschermen tegen de cytotoxische werking van cytostatica. 
Er wordt een overzicht gegeven van de preklinische en klinische studies over 
GSTs en cytostatica resistentie. Vele preklinische onderzoeken lieten een 
correlatie zien tussen GSTs en chemotherapie resistentie. 
De zeer summiere resultaten van klinische studies daarentegen zijn niet 
eensluidend. Dientengevolge blijft de rol van GSTs bij chemotherapie resistentie 
nog onduidelijk. 
Hoofdstuk 4: Celproliferatie 
Bepaling van celproliferatie kan belangrijke informatie verschaffen over het 
klinische gedrag van verschillende tumoren. In hoofdstuk 4 worden diverse 
methoden voor de bepaling van celproliferatie besproken. De voor- en nadelen 
van de verschillende methoden worden bediscussieerd. Bovendien wordt een 
overzicht gegeven van onderzoeken die de prognostische waarde van 
celproliferatie bij het maagcarcinoom bestudeerden. Er wordt geconcludeerd dat 
op grond van gegevens uit de literatuur erweliswaarsterke aanwijzingen zijn dat 
bepaling van celproliferatie een bepaalde prognostische waarde kan hebben, 
maar dat nieuwe multivariate analyses noodzakelijk zijn om na te gaan of 
celproliferatie een onafhankelijke prognostische parameter is. 
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Hoofdstuk 5: Immunohistochemische bepaling van GSTs. 
De betekenis van GSTs bij het maagcarcinoom, zowel als prognostische 
parameter als ook als parameter voor respons op chemotherapie, vormt een 
belangrijk onderdeel van de vraagstelling van deze dissertatie. Om de 
werkingsmechanismen van de GSTs te kunnen begrijpen en verklaren, is kennis 
omtrent de expressie van GSTs essentieel. Daarom werd een 
immunohistochemischedetectiemethodevoorGSTklasseAlpha en Pi ontwikkeld. 
In hoofdstuk 5 wordt de expressie van GST klasse Alpha en Pi bestudeerd in 
normale maagmucosa en in maagcarcinoom. GST Alpha en Pi waren in 
respectievelijk 47 en 100 procent van de tumoren aanwezig. In normaal 
maagweefsel kwamen GST Alpha en Pi in respectievelijk 88 en 97 procent van 
de coupes tot expressie in muceuze cellen, in parietaal cellen in 93 en 67 procent 
en in hoofdcellen in 82 en 30 procent van de coupes. 
Hoofdstuk 6: Vergelijking tussen biochemische en immunohistochemische 
bepaling van GSTs 
De expressie van GST klasse Alpha en Pi kan worden bepaald met behulp van 
een immunohistochemische bepalingsmethode (zie hoofdstuk 5), maar ook met 
een biochemische methode. In hoofdstuk 6 worden de resultaten van beide 
methoden met elkaar vergeleken. Noch in normale maagmucosa, noch in 
maagcarcinoom, werd een significante correlatie gevonden tussen beide 
methoden. De mogelijkeoorzaken voordeze discrepantie worden bediscussieerd. 
Hoofdstuk 7: Correlatie van GSTs met de overleving 
In dit hoofdstuk wordt de relatie bestudeerd tussen enerzijds de biochemische 
expressie van GSTs in normaal en maligne maagweefsel en anderzijds de 
klinische kenmerken, inclusief de overleving, bij 49 patiënten met een 
maagcarcinoom, die allen chirurgisch werden behandeld. Erwerd geen correlatie 
gevonden tussen GST parameters en tumor stadium, tumor localisatie, mate van 
eosinofilie in de tumor, aanwezigheid van intestinale metaplasie, of geslacht of 
leeftijd van de patiënt. 
Na optimale dichotomisatie van de GST parameters werden univariate en 
multivariate analyses verricht om een mogelijke associatie tussen GSTs en 
overleving te onderzoeken. De resultaten van deze analyses toonden dat een 
hoge waarde van GST Pi in normaal en maligne maagweefsel, evenals de 
aanwezigheid van GST Mu van significant prognostische waarde waren voor de 
overleving, onafhankelijk van de klinische kenmerken. 
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Hoofdstuk 8: Vergelijking tussen "in vivo" iododeoxyuridine labelling index (Idil 
LI) en MIB-1 LI 
In hoofdstuk 8 worden 2 verschillende methoden om celproliferatie te bepalen 
vergeleken. In normaal maagweefsel en tumorweefsel van 20 patiënten meteen 
maagcarcinoom werd de proliferatieve activiteit bepaald na "in vivo" labeling met 
IdU en na kleuring met het MIB-1 antilichaam. 
In de normale maagmucosa werd een significante correlatie gevonden tussen 
beide methoden, echter in tumorweefsel was er geen signifcante correlatie. 
Daarom dient voorzichtigheid betracht te worden bij de interpretatie van MIB-1 
immunohistochemische kleuringen of van IdU labelling bij maagcarcinomen. 
Hoofdstuk 9: De rol van glutathion (GSH), GSTs, P-170 glycoproteine (Pgp), 
multidrug resistance associated protein (MRP) en IdU LI bij het optreden van 
resistentie tegen chemotherpapie bij het maagcarcinoom 
Resistentie tegen chemotherapie komt vaak voor bij het maagcarcinoom. 
Wanneer het mechanisme van resistentie kan worden ontrafeld, zal dit 
waarschijnlijk kunnen leiden tot een meer effectieve behandeling. Daarom is het 
van groot belang te onderzoeken welke factoren een rol spelen bij resistentie. 
In dit hoofdstuk wordt de rol van GSTs, Pgp, MRP en IdU LI als parameter voor 
respons en resistentie tegen chemotherapie bij het maagcarcinoom beschreven. 
Bij 15 patiënten met een maagcarcinoom, die werden behandeld met 
chemotherapie werden voorstart van behandeling, na 2 kuren chemotherapie en 
na het staken van de behandeling, biopten genomen uit normale maagmucosa 
en uit het maagcarcinoom. In deze biopten werd de expressie van GSTs, Pgp, 
MRP en de IdU LI bepaald. 
Geen van de bovengenoemde parameters had een voorspellende waarde voor 
de respons op chemotherapie. Wel werden er tijdens de behandeling met 
chemotherapie significante verschillen gevonden in GSH, GST activiteit en GST 
Pi expressie tussen patiënten, die goede reactie op chemotherapie vertoonden, 
en patiënten die niet reageerden op chemotherapie. Dit suggereert dat er bij het 
optreden van chemotherapie resistentie mogelijk een rol is voor het GST/GSH 
systeem. 
Conclusies en aanbevelingen voor verder onderzoek 
Bij tumoren met een slechte prognose, zoals het maagcarcinoom, kunnen 
prognostische parameters van groot belang zijn. Wij vonden dat biochemisch 
bepaalde GST parameters een onafhankelijke voorspellende waarde hadden 
voor de overleving. Het zou waardevol zijn om in de toekomst een prospectieve 
studie te verrichten naar de prognostische betekenis van GSTs bij het 
maagcarcinoom. 
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In de literatuurverschijnen er steeds meer aanwijzingen dat een hoge expressie 
van GST Pi kenmerkend is voor maligne transformatie. Het zal van groot belang 
zijn de rol van GST Pi te bestuderen in premaligne aandoeningen van de maag, 
zoals atrofische gastritis. 
In deze dissertatie werd cel proliferatie van hetmaagcarcinoom bestudeerd met 
behulp van de "in vivo" IdU LI en het MIB-1 antilichaam. Zoals beschreven zijn er 
vele methoden om celproliferatie te meten. Bij vergelijking van verschillende 
proliferatiemarkers werden wisselende resultaten gevonden. Vaak werd een 
goede correlatie gevonden tussen 2 proliferatiemarkers. Er zijn echter ook veel 
studies beschreven, waarin geen significantie werd gevonden tussen 2 
proliferatiemarkers. In ons onderzoek werd een goede correlatie gevonden 
tussen "in vivo" IdU LI en MIB-1 LI in normale maagmucosa, maar niet in het 
maagcarcinoom. Hiermee zal rekening gehouden moeten worden bij toekomstige 
studies. 
De betekenis van GSH, GSTs, Pgp, MRP en celproliferatie als parameter voor 
respons op chemotherapie werd onderzocht in hoofdstuk 9. Geen van deze 
parameters had een voorspellende waarde. Echter, deze studie werd verricht in 
een kleine, heterogene groep patiënten. Om tot een goed gefundeerde uitspraak 
te kunnen komen zal een grote multicenter studie moeten worden gestart. 
De vraagstelling van deze dissertatie was de rol van de GSTs als parameter voor 
prognose en voor respons op chemotherapie te bestuderen. Er kan worden 
geconcludeerd dat in onze studies biochemisch bepaalde GST parameters 
onafhankelijke voorspellende waarde voor de overleving hadden bij patiënten 
met een maagcarcinoom, die chirurgisch werden behandeld. Er werd echter 
geen significante correlatie gevonden tussen GST parameters en de respons op 
chemotherapie. 
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analisteaan hetonderzoekgewerkt.Jouwenthousiastemaniervanwerken, jouw 
inbreng en je vriendschap heb ik erg gewaardeerd. Ik ben blij, dat je me ook bij 
de promotie als paranimf ter zijde wilt staan. 
Alle collegae van de afdeling Maag-, darm- en leverziekten en van de afdeling 
Medische Oncologie, de medewerkers van het laboratorium en van de afdeling 
Endoscopie, wil ik bedanken voor hun belangstelling voor de voortgang van dit 
onderzoek. 
Een belangrijk deel van dit proefschrift beschrijftimmunohistochemisch onderzoek. 
De hulp van de afdeling Pathologie was hierbij onontbeerlijk. Prof. Dr. U. van 
Haelst, Dr. A.A.J. Verhofstad en Wil Lange ben ik veel dank verschuldigd. 
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De statistische analyses werden verricht door Georg Born, Anja Koster en Nelly 
Peer van de Medisch Statistische Afdeling. 
Theo Mulder wijdde mij in in de wereld van de survival analyse. Zonder jouw hulp 
was van hoofdstuk 7 niet veel terecht gekomen. 
Jose Benneker, Anita Huisman en Saskia van de Velde van de afdeling Klinische 
Farmacie zorgden voor het beschikbaar stellen van iododeoxyuridine. 
Een deel van de patiënten, die deelnamen aan het onderzoek waren afkomstig 
van de afdeling chirurgie uit het Academisch Ziekenhuis Nijmegen en uit perifere 
ziekenhuizen. Ik wil Rigtje van der Sluis en Theo Wobbes van de afdeling 
chirurgie en alle oncologen, gastroenterologen en chirurgen uit het Slingeland 
Ziekenhuis in Doetinchem, het Laurentius Ziekenhuis in Roermond en Ziekenhuis 
Rijnstate te Arnhem, die hun medewerking hebben verleend, bedanken voor hun 
hulp bij het selecteren van patiënten voor het onderzoek. 
Dit onderzoek werd mogelijk gemaakt door financiële steun van het Koningin 
Wilhelmina Fonds. 
In Ziekenhuis Rijnstate werd ik opgeleid tot internist. Tevens vindt een deel van 
mijn opleiding tot maag-, darm- en leverarts hier plaats. Ik wil de leden van de 
maatschap interne geneeskunde en in het bijzonder de maag-, darm- en 
leverartsen bedanken voor hun bijdrage aan mijn opleiding. De enthousiaste 
manier waarop het vak bedreven wordt is zeer stimulerend. 
De combinatie van een gezin en het verrichten van promotieonderzoek is niet 
altijd gemakkelijk. Iedereen, die op welke wijze dan ook, heeft geholpen om thuis 
alles goed te laten verlopen, wil ik hartelijk bedanken. 
Mijn ouders wil ik niet alleen bedanken voor het feit, dat zij mij in de gelegenheid 
hebben gesteld om geneeskunde te studeren, maar ook voor de warme 
belangstelling voor en het vertrouwen in het werk dat ik deed. Jullie stonden altijd 
voor mij klaar, als dat nodig was. 
Lieve Arnoud, jij zorgde voorde lay-out van dit proefschrift. Maarjij deed nog veel 
meer. Elke avond en elke zaterdag als ik me op sloot op de studeerkamer, zorgde 
jij dat thuis alles op rolletjes bleef lopen. Zonder jouw onvoorwaardelijke steun 
was de combinatie van een gezin en het verrichten van promotieonderzoek 
absoluut onmogelijk geweest. Vanaf nu zal er meer tijd zijn voor jou en voor 
Marieke en Evelien. 
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1980 Eindexamen Gymnasium - ß aan het Christelijk Lyceum Almelo 
1980 Start studie Geneeskunde aan de Rijksuniversiteit Groningen 
1985 Student-assistentschap op de afdeling Interne Oncologie in het Academisch 
Ziekenhuis Groningen (begeleider Dr E G E de Vnes) 
1987 Artsexamen Rijksuniversiteit Groningen 
1987 Start opleiding tot internist in het Gemeenteziekenhuis te Arnhem, later 
Ziekenhuis Rijnstate 
Opleiders Dr К H Brandt en Dr J M Werre 
1992 Registratie als internist 
1992 Werkzaam als KWF fellow op de afdeling Medische Oncologie (Hoofd 
Prof Dr D J Τ Wagener) en op de afdeling Maag-, darm- en leverziekten 
(Hoofd Prof Dr J В M J Jansen) in het Academisch Ziekenhuis Nijmegen 
1996 Start opleiding tot maag-, darm- en leverarts in het Academisch Ziekenhuis 
Nijmegen Opleider Prof Dr J В M J Jansen 
1996 Detachering naarde afdeling Maag-, darm- en leverziekten van Ziekenhuis 
Rijnstate te Arnhem in het kader van de opleiding tot maag-, darm- en 
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ZIJ IS getrouwd met Amoud Kunst en heeft twee dochters, Marieke en 
Evelien 
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Stellingen 
behorende bij het proefschrift 
Chemotherapy resistance in gastric cancer 
The role of glutathione S-transferases and other mechanisms 
Lucette Schipper 
Nijmegen, 11 december 1997 
1 Ongeveerde helft van de patiënten met een gemetastaseerd maagcarcinoom 
profiteert van behandeling met chemotherapie, door reductie van klachten of 
verlenging van overleving 
Dit proefschrift 
2 Glutathione S-transferase Alpha komt vooral tot expressie in panetaalcellen 
en muceuze cellen, terwijl glutathione S-transferase Pi met name aanwezig 
is in tumorcellen en in mindere mate in muceuze cellen 
Dit proefschrift 
3 Gezien de vele bepalingsmethoden, die gebruikt kunnen worden om 
celproliferatie te meten, is goed vergelijkend onderzoek en uniformering van 
methode essentieel 
4 Een hoge biochemische waarde van glutathion S-transferase Pi en de 
aanwezigheid van glutathion S-transferase Mu in normaal en maligne 
maagweefsel lijken van significant prognostische waarde voorde overleving, 
onafhankelijk van klinische kenmerken 
Dit proefschrift 
5 Vele gastroenterologen hebben een te ongenuanceerde oordeel over 
chemotherapeutische behandeling van gastrointestinale tumoren 
6 Een multidisciplinaire benadering is een belangrijke voorwaarde voor 
behandeling van gastrointestinale mahgniteiten 
7 Wil de gastroenterologie de meest talentvolle vrouwelijke artsen voor zich 
winnen dan zal er actief gewerkt moeten worden aan beleid ten aanzien van 
zwangerschaps- en ouderschapsverlof tijdens hun opleiding tot 
gastroenteroloog 
Inaugurele rede Prof Dr JB MJ Jansen, Werken tussen uitersten 
8 Een goede balans van praten, denken en doen maakt van geneeskunde 
geneeskunst 
9 Tijdsgebrek is een nieuwe vorm van armoede 
Мщат Schoettelndreier, Volkskrant 6juli 1996 
10. Positieve discriminatie is ook discriminatie. 
11. Een goede dokter leeft niet alleen voor het werk. 
12. Daar kinderen soms hele zinnige opmerkingen maken en volwassenen 
regelmatig erg onzinnige dingen beweren, is het gezegde "het verstand komt 
met de jaren" onjuist. 
13. Door toenemend gebruik van de digitale snelweg zal de vereenzaming nog 
verder stijgen. 



